Amedeo Smart

Free Medical Literature Service

 

Amedeo

Inflammatory Bowel Diseases
  Free Subscription

Articles published in
Aliment Pharmacol Ther
    May 2024
  1. NEDUMANNIL L, Mohamedrashed M, Bohra A, Sood S, et al
    Letter: The emerging role of novel capsule endoscopy systems in gastroenterology with specific reference to small bowel Crohn's disease.
    Aliment Pharmacol Ther. 2024;59:1162-1163.
    >> Share

  2. BARTH I, Stevens CL, Strokap CJ, Campmans-Kuijpers MJE, et al
    Letter: Diet-microbiome interactions in inflammatory bowel disease-Navigating towards individualised dietary strategies.
    Aliment Pharmacol Ther. 2024;59:1154-1155.
    >> Share

  3. THWAITES PA, Gibson PR
    Letter: The emerging role of novel capsule endoscopy systems in gastroenterology with specific reference to small bowel Crohn's disease. Authors' reply.
    Aliment Pharmacol Ther. 2024;59:1164-1165.
    >> Share

  4. SEIDELIN JB
    Editorial: Time to address quality of life in our IBD treatment-IBD nurse intervention as a key part of multimodal IBD management.
    Aliment Pharmacol Ther. 2024;59:1152-1153.
    >> Share

    April 2024
  5. ALIU A, Bosch DHCA, Keszthelyi D, Rezazadeh Ardabili A, et al
    Review article: A practical approach to persistent gastrointestinal symptoms in inflammatory bowel disease in remission.
    Aliment Pharmacol Ther. 2024 Apr 8. doi: 10.1111/apt.17988.
    >> Share

  6. VASUDEVAN A, Con D, van Langenberg DR
    Letter: Thioguanine, an under-utilised option in inflammatory bowel disease? Authors' reply.
    Aliment Pharmacol Ther. 2024;59:1011.
    >> Share

  7. ASONUMA K, Sagami S, Kobayashi T
    Letter: Modifying the Mayo endoscopic subscore for improved prognostic insights.
    Aliment Pharmacol Ther. 2024;59:1005-1006.
    >> Share

  8. CHETWOOD JD, Paramsothy S, Leong RW
    Letter: Thioguanine, an underutilised option in inflammatory bowel disease?
    Aliment Pharmacol Ther. 2024;59:1009-1010.
    >> Share

    March 2024
  9. AKIYAMA S, Yokoyama K, Yagi S, Shinzaki S, et al
    Efficacy and safety of filgotinib for ulcerative colitis: A real-world multicenter retrospective study in Japan.
    Aliment Pharmacol Ther. 2024 Mar 17. doi: 10.1111/apt.17961.
    >> Share

  10. RICCIUTO A, Liu K, El-Matary W, Amin M, et al
    Oral vancomycin is associated with improved inflammatory bowel disease clinical outcomes in primary sclerosing cholangitis-associated inflammatory bowel disease (PSC-IBD): A matched analysis from the Paediatric PSC Consortium.
    Aliment Pharmacol Ther. 2024 Mar 10. doi: 10.1111/apt.17936.
    >> Share

  11. GARCIA MJ, Riestra S, Amiot A, Julsgaard M, et al
    Effectiveness and safety of a third-line rescue treatment for acute severe ulcerative colitis refractory to infliximab or ciclosporin (REASUC study).
    Aliment Pharmacol Ther. 2024 Mar 6. doi: 10.1111/apt.17938.
    >> Share

  12. LU C, Rosentreter R, Delisle M, White M, et al
    Systematic review: Defining, diagnosing and monitoring small bowel strictures in Crohn's disease on intestinal ultrasound.
    Aliment Pharmacol Ther. 2024 Mar 4. doi: 10.1111/apt.17918.
    >> Share

  13. GONCZI L, Lakatos L, Ilias A, Lakatos PL, et al
    Editorial: The prevalence and outcomes of perianal Crohn's disease across the treatment eras-Authors' reply.
    Aliment Pharmacol Ther. 2024;59:715-716.
    >> Share

  14. LENFANT M, Verstockt B, Sabino J, Vermeire S, et al
    Letter: Should ulcerative colitis be monitored more or less invasively? Authors' reply.
    Aliment Pharmacol Ther. 2024;59:723-724.
    >> Share

  15. LAHARIE D
    Letter: Should ulcerative colitis be monitored more or less invasively?
    Aliment Pharmacol Ther. 2024;59:721-722.
    >> Share

  16. TASSONE D, Hartley I, Ding NS
    Editorial: The prevalence and outcomes of perianal Crohn's disease across treatment eras.
    Aliment Pharmacol Ther. 2024;59:713-714.
    >> Share

  17. VAN LIERE ELSA, de Boer NKH
    Editorial: Towards optimal thiopurine therapy for inflammatory bowel disease.
    Aliment Pharmacol Ther. 2024;59:792-793.
    >> Share

  18. VASUDEVAN A, Con D, van Langenberg DR
    Editorial: Towards optimal thiopurine therapy for inflammatory bowel disease-authors' reply.
    Aliment Pharmacol Ther. 2024;59:794.
    >> Share

  19. BOKEMEYER B, Plachta-Danielzik S, Steiner IM, Pohlschneider D, et al
    Inflammatory bowel disease (IBD) patients with impaired quality of life on biologic therapy benefit from the support of an IBD nurse specialist: Results of a randomised controlled trial in Germany (IBD(BIO-ASSIST) study).
    Aliment Pharmacol Ther. 2024 Mar 1. doi: 10.1111/apt.17926.
    >> Share

    February 2024
  20. ERIKSSON C, Sun J, Bryder M, Broms G, et al
    Impact of inflammatory bowel disease on the risk of acute coronary syndrome: A Swedish Nationwide Cohort Study.
    Aliment Pharmacol Ther. 2024 Feb 29. doi: 10.1111/apt.17932.
    >> Share

  21. ZAMANI M, Alizadeh-Tabari S, Murad MH, Ananthakrishnan AN, et al
    Meta-analysis: Risk of pancreatic cancer in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2024 Feb 19. doi: 10.1111/apt.17919.
    >> Share

  22. SAGAMI S, Kobayashi T
    Editorial: Extending upadacitinib induction dosing in ulcerative colitis-A delicate balance of efficacy and safety.
    Aliment Pharmacol Ther. 2024;59:579-580.
    >> Share

  23. PANACCIONE R
    Editorial: Extending upadacitinib induction dosing in ulcerative colitis-A delicate balance of efficacy and safety. Author's reply.
    Aliment Pharmacol Ther. 2024;59:581-582.
    >> Share

  24. VASUDEVAN A, Con D, De Cruz P, Sparrow MP, et al
    Clinical trial: Combination allopurinol-thiopurine versus standard thiopurine in patients with IBD escalating to immunomodulators (the DECIDER study).
    Aliment Pharmacol Ther. 2024;59:504-514.
    >> Share

    January 2024
  25. CON D, Srinivasan A
    Letter: Comparing first-line infliximab and vedolizumab for ulcerative colitis-it depends on how you use the drug.
    Aliment Pharmacol Ther. 2024;59:140-141.
    >> Share

  26. VAN DE MEEBERG MM, Fidder HH, de Jonge R, Bouma G, et al
    Editorial: Monitoring methotrexate polyglutamates in Crohn's disease-Authors' reply.
    Aliment Pharmacol Ther. 2024;59:120-121.
    >> Share

  27. BARCLAY ML, Stamp LK
    Editorial: Monitoring methotrexate polyglutamates in Crohn's disease.
    Aliment Pharmacol Ther. 2024;59:118-119.
    >> Share

  28. PRAY C, Narula N
    Editorial: Moving towards prognostic endoscopic scoring in IBD.
    Aliment Pharmacol Ther. 2024;59:132-133.
    >> Share

    December 2023
  29. GONCZI L, Lakatos L, Golovics PA, Angyal D, et al
    Burden of perianal disease in Crohn's disease: Accelerating medical therapy and high rates of perianal surgery over the last four decades - Results from a population-based study over four decades.
    Aliment Pharmacol Ther. 2023 Dec 19. doi: 10.1111/apt.17836.
    >> Share

  30. MEYER A, Dong C, Chan SSM, Touvier M, et al
    Dietary index based on the Food Standards Agency nutrient profiling system and risk of Crohn's disease and ulcerative colitis.
    Aliment Pharmacol Ther. 2023 Dec 15. doi: 10.1111/apt.17835.
    >> Share

  31. DESAI A, Regueiro M, Kochhar GS
    Letter: Tofacitinib, vedolizumab and ustekinumab in patients with ulcerative colitis-Authors' reply.
    Aliment Pharmacol Ther. 2023;58.
    >> Share

  32. SOHN J
    Editorial: Unravelling the relationship between periodontal disease and inflammatory bowel disease.
    Aliment Pharmacol Ther. 2023;58.
    >> Share

  33. REZAZADEH ARDABILI A, Janssen L, Mujagic Z
    Letter: Abdominal pain in patients with inflammatory bowel disease in remission - A look beyond psychosocial factors. Authors' reply.
    Aliment Pharmacol Ther. 2023;58.
    >> Share

  34. CHANG HC, Gau SY
    Letter: Tofacitinib, vedolizumab and ustekinumab in patients with ulcerative colitis.
    Aliment Pharmacol Ther. 2023;58.
    >> Share

  35. BASSOTTI G, Villanacci V, Maconi G
    Letter: Abdominal pain in inflammatory bowel disease patients in remission-A look beyond psychosocial factors.
    Aliment Pharmacol Ther. 2023;58.
    >> Share

    November 2023
  36. BUISSON A, Nachury M, Bazoge M, Yzet C, et al
    Long-term effectiveness and acceptability of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel disease treated with intensified doses: The REMSWITCH-LT study.
    Aliment Pharmacol Ther. 2023 Nov 30. doi: 10.1111/apt.17822.
    >> Share

  37. PEYRIN-BIROULET L, Vermeire S, D'Haens G, Panes J, et al
    Clinical trial: Clinical and endoscopic outcomes with ustekinumab in patients with Crohn's disease: Results from the long-term extension period of STARDUST.
    Aliment Pharmacol Ther. 2023 Nov 30. doi: 10.1111/apt.17751.
    >> Share

  38. PANACCIONE R, Danese S, Zhou W, Klaff J, et al
    Efficacy and safety of upadacitinib for 16-week extended induction and 52-week maintenance therapy in patients with moderately to severely active ulcerative colitis.
    Aliment Pharmacol Ther. 2023 Nov 27. doi: 10.1111/apt.17816.
    >> Share

  39. BOKEMEYER B, Plachta-Danielzik S
    Letter: Comparing first-line infliximab and vedolizumab for ulcerative colitis-It depends on how you use the drug. Authors' reply.
    Aliment Pharmacol Ther. 2023 Nov 4. doi: 10.1111/apt.17796.
    >> Share

  40. KELLER JJ, Terveer EM
    Editorial: Continuous monitoring to improve outcome of treatment-the next step towards safe and effective faecal microbiota transplantation.
    Aliment Pharmacol Ther. 2023;58:946-947.
    >> Share

  41. DAN L, Wang X, Chen J
    Editorial: Unravelling the fibres-low dietary fibre may lower risk of developing IBD. Authors' reply.
    Aliment Pharmacol Ther. 2023;58:940-941.
    >> Share

  42. LOPES EW, Khalili H
    Editorial: Unravelling the fibres-low dietary fibre may lower risk of developing IBD.
    Aliment Pharmacol Ther. 2023;58:938-939.
    >> Share

    October 2023
  43. SPARTZ EJ, DeDecker LC, Fansiwala KM, Noorian S, et al
    Recent trends and risk factors associated with Clostridioides difficile infections in hospitalized patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2023 Oct 24. doi: 10.1111/apt.17777.
    >> Share

  44. LENFANT M, Verstockt B, Sabino J, Vermeire S, et al
    The assessment of segmental healing by the Modified Mayo Endoscopic Score (MMES) complements the prediction of long-term clinical outcomes in patients with ulcerative colitis.
    Aliment Pharmacol Ther. 2023 Oct 16. doi: 10.1111/apt.17753.
    >> Share

  45. DAJTI E, Frazzoni L, Iascone V, Secco M, et al
    Systematic review with meta-analysis: Diagnostic performance of faecal calprotectin in distinguishing inflammatory bowel disease from irritable bowel syndrome in adults.
    Aliment Pharmacol Ther. 2023 Oct 12. doi: 10.1111/apt.17754.
    >> Share

  46. KAYAL M, Meringer H, Martin L, Colombel JF, et al
    Scores used to predict outcomes in acute severe ulcerative colitis: A systematic review.
    Aliment Pharmacol Ther. 2023 Oct 11. doi: 10.1111/apt.17731.
    >> Share

  47. RIGGOTT C, Fairbrass KM, Black CJ, Gracie DJ, et al
    Novel symptom clusters predict disease impact and healthcare utilisation in inflammatory bowel disease: Prospective longitudinal follow-up study.
    Aliment Pharmacol Ther. 2023 Oct 4. doi: 10.1111/apt.17735.
    >> Share

  48. WILLIAMS KM, Challa PK, Lopes EW, Burke KE, et al
    Periodontal disease is not associated with risk of inflammatory bowel disease: Results from two prospective cohort studies in the US.
    Aliment Pharmacol Ther. 2023 Oct 2. doi: 10.1111/apt.17732.
    >> Share

  49. TASSONE D, Hartley I, Ding NS
    Letter: Muscle thickness measurement using ultrasound-A step closer to the use of body composition analysis in the management of inflammatory bowel disease.
    Aliment Pharmacol Ther. 2023;58:729-730.
    >> Share

  50. ANDREW B, Zhou A, Trinh S, Srinivasan A, et al
    Letter: Antibiotics in gut dysbiosis and development of inflammatory bowel disease-More thought is needed.
    Aliment Pharmacol Ther. 2023;58:838-839.
    >> Share

  51. OH SJ, Kim HJ, Lee CK
    Letter: Antibiotics in gut dysbiosis and development of inflammatory bowel disease-More thought is needed-Authors' reply.
    Aliment Pharmacol Ther. 2023;58:840-841.
    >> Share

  52. ARULJOTHY A, Singh S, Narula N, Moran GW, et al
    Systematic review with meta-analysis: Medical therapies for treatment of ulcerative proctitis.
    Aliment Pharmacol Ther. 2023;58:740-762.
    >> Share

  53. REZAZADEH ARDABILI A, Van Bodegraven AA
    Editorial: IBD cost evolution - transitioning from compensating lost productivity to escalating medication expenses.
    Aliment Pharmacol Ther. 2023;58:832-833.
    >> Share

    September 2023
  54. VAN DE MEEBERG MM, Fidder HH, Oldenburg B, Sundaresan J, et al
    Therapeutic drug monitoring of methotrexate in patients with Crohn's disease.
    Aliment Pharmacol Ther. 2023 Sep 28. doi: 10.1111/apt.17719.
    >> Share

  55. FAQERAH N, Walker D, Gerasimidis K
    Review article: The complex interplay between diet and Escherichia coli in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2023 Sep 28. doi: 10.1111/apt.17720.
    >> Share

  56. JANSSEN LM, Rezazadeh Ardabili A, Romberg-Camps MJL, Winkens B, et al
    Abdominal pain in patients with inflammatory bowel disease in remission: A prospective study on contributing factors.
    Aliment Pharmacol Ther. 2023 Sep 19. doi: 10.1111/apt.17718.
    >> Share

  57. SCHREIBER S, Rogler G, Watanabe M, Vermeire S, et al
    Integrated safety analysis of filgotinib for ulcerative colitis: Results from SELECTION and SELECTIONLTE.
    Aliment Pharmacol Ther. 2023 Sep 18. doi: 10.1111/apt.17674.
    >> Share

  58. ANDREW B, Srinivasan A, Zhou A, Vasudevan A, et al
    Letter: Elderly onset inflammatory bowel disease-Treat to target approach is still warranted.
    Aliment Pharmacol Ther. 2023;58:556-557.
    >> Share

  59. YAMAMOTO T
    Editorial: Is vedolizumab the preferred biologic therapy for biologic-naive patients with ulcerative colitis?
    Aliment Pharmacol Ther. 2023;58:546-547.
    >> Share

  60. DIGNASS A, Rath S, Kleindienst T, Stallmach A, et al
    Review article: Translating STRIDE-II into clinical reality - Opportunities and challenges.
    Aliment Pharmacol Ther. 2023;58:492-502.
    >> Share

  61. WU X, Yang Y
    Letter: Chinese herbal medicine Curcumin-QingDai (CurQD) - A good treatment option for active ulcerative colitis?
    Aliment Pharmacol Ther. 2023;58:640.
    >> Share

  62. DIGNASS A, Rath S, Kleindienst T, Stallmach A, et al
    Editorial: If STRIDE-II is the hammer, then Crohn's disease and ulcerative colitis are not the same nails-Authors' reply.
    Aliment Pharmacol Ther. 2023;58:634-635.
    >> Share

  63. KEDIA S, Ahuja V
    Editorial: If STRIDE-II is the hammer, then Crohn's disease and ulcerative colitis are not the same nails.
    Aliment Pharmacol Ther. 2023;58:632-633.
    >> Share

  64. YANAI H, Salomon N, Ben-Horin S, Kopylov U, et al
    Letter: Chinese herbal medicine Curcumin-QingDai (CurQD)-A good treatment option for active ulcerative colitis? Authors' reply.
    Aliment Pharmacol Ther. 2023;58:641.
    >> Share

    August 2023
  65. HONAP S, Peyrin-Biroulet L
    Review article: Externally derived control arms-An opportunity for clinical trials in inflammatory bowel disease?
    Aliment Pharmacol Ther. 2023 Aug 21. doi: 10.1111/apt.17684.
    >> Share

  66. EVERHOV AH, Soderling J, Befrits G, Khalili H, et al
    Increasing healthcare costs in inflammatory bowel disease 2007-2020 in Sweden.
    Aliment Pharmacol Ther. 2023 Aug 18. doi: 10.1111/apt.17675.
    >> Share

  67. WOELFEL S, Dutschler J, Konig M, Dulovic A, et al
    STAR SIGN study: Evaluation of COVID-19 vaccine efficacy against the SARS-CoV-2 variants BQ.1.1 and XBB.1.5 in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2023 Aug 12. doi: 10.1111/apt.17661.
    >> Share

  68. LOBATON T, Truyens M
    Editorial: LAG-3-depleting monoclonal antibody: a potential treatment for patients with ulcerative colitis?
    Aliment Pharmacol Ther. 2023;58:359-360.
    >> Share

  69. KANE S
    Editorial: Increased risk of cervical dysplasia with immunomodulator use in IBD.
    Aliment Pharmacol Ther. 2023;58:357-358.
    >> Share

  70. KIRCHGESNER J, Beaugerie L
    Editorial: Pip pip to PIPs (post- inflammatory polyps) as a neoplasia risk factor in IBD? Authors' reply.
    Aliment Pharmacol Ther. 2023;58:363.
    >> Share

  71. TASSONE D, Hartley I, Ding NS
    Letter: Combatting sarcopenia to improve clinical outcomes in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2023;58:376-377.
    >> Share

  72. VELAYOS FS
    Editorial: Pip pip to PIP's (post-inflammatory polyps) as a neoplasia risk factor in IBD?
    Aliment Pharmacol Ther. 2023;58:361-362.
    >> Share

    July 2023
  73. DENG M, Dan L, Ye S, Chen X, et al
    Higher dietary fibre intake is associated with lower risk of inflammatory bowel disease: prospective cohort study.
    Aliment Pharmacol Ther. 2023 Jul 18. doi: 10.1111/apt.17649.
    >> Share

  74. MIN Y, Wei X, Peng X
    Letter: Mendelian randomization-New perspective in inflammatory bowel disease and pancreatic cancer?
    Aliment Pharmacol Ther. 2023;58:143-144.
    >> Share

  75. MASSIRONI S, Vigano C, Danese S
    Letter: Mendelian randomization - new perspective in inflammatory bowel disease and pancreatic cancer? Authors' reply.
    Aliment Pharmacol Ther. 2023;58:145-146.
    >> Share

  76. MILES M, Nasser Y
    Editorial: faecal incontinence in ulcerative colitis.
    Aliment Pharmacol Ther. 2023;58:114-115.
    >> Share

  77. CHAN P, Connor S, Huang V, Karimi N, et al
    Letter: expanding the role for decision aids in IBD into pregnancy-related topics.
    Aliment Pharmacol Ther. 2023;58:141-142.
    >> Share

  78. ESTEVINHO MM, Magro F
    Editorial: elderly onset inflammatory bowel disease - clues from the largest population-based cohort study.
    Aliment Pharmacol Ther. 2023;58:116-117.
    >> Share

  79. HUDSON AS, Huynh HQ
    Editorial: Predicting paediatric ulcerative colitis outcomes-how can we improve?
    Aliment Pharmacol Ther. 2023;58:258-259.
    >> Share

  80. OH SJ, Kim HJ, Lee CK
    Editorial: Antibiotics and risk of IBD-Can we close the books? Authors' reply.
    Aliment Pharmacol Ther. 2023;58:256-257.
    >> Share

  81. EBRAHIMI F, Forss A
    Editorial: Antibiotics and risk of IBD-Can we close the books?
    Aliment Pharmacol Ther. 2023;58:254-255.
    >> Share

  82. BACSUR P, Ilias A, Resal T, Kata D, et al
    Letter: Experience of switching vedolizumab treatment from intravenous to subcutaneous formulation in Hungary.
    Aliment Pharmacol Ther. 2023;58:262-263.
    >> Share

    June 2023
  83. D'HAENS G, Peyrin-Biroulet L, Marks DJB, Lisi E, et al
    A randomised, double-blind, placebo-controlled study of the LAG-3-depleting monoclonal antibody GSK2831781 in patients with active ulcerative colitis.
    Aliment Pharmacol Ther. 2023 Jun 16. doi: 10.1111/apt.17557.
    >> Share

  84. BOKEMEYER B, Plachta-Danielzik S, di Giuseppe R, Efken P, et al
    Real-world effectiveness of vedolizumab compared to anti-TNF agents in biologic-naive patients with ulcerative colitis: A two-year propensity-score-adjusted analysis from the prospective, observational VEDO(IBD) -study.
    Aliment Pharmacol Ther. 2023 Jun 15. doi: 10.1111/apt.17616.
    >> Share

  85. NGUYEN AL, Burns M, Herath M, Lambell K, et al
    Accuracy of ultrasound, bioelectrical impedance analysis and anthropometry as point-of-care measurements of skeletal muscle mass in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2023 Jun 12. doi: 10.1111/apt.17607.
    >> Share

  86. KOCHHAR GS, Desai A, Farraye FA, Cross RK, et al
    Efficacy of biologic and small molecule agents as second-line therapy after exposure to TNF inhibitors in patients with ulcerative colitis: A propensity-matched cohort study.
    Aliment Pharmacol Ther. 2023 Jun 9. doi: 10.1111/apt.17570.
    >> Share

  87. MACALUSO FS, Orlando A
    Editorial: adjuvanted recombinant zoster vaccine in adults with inflammatory bowel disease-time for universal recommendation?
    Aliment Pharmacol Ther. 2023;57:1343-1344.
    >> Share

  88. CALDERA F, Spaulding AC, Hayney MS, Farraye FA, et al
    Editorial: adjuvanted recombinant zoster vaccine in adults with inflammatory bowel disease-time for universal recommendation? Authors' reply.
    Aliment Pharmacol Ther. 2023;57:1345-1346.
    >> Share

  89. CHEN P, Chen F
    Letter: 1-kestose, the smallest fructooligosaccharide component, protection for mild to moderate ulcerative colitis patients.
    Aliment Pharmacol Ther. 2023;57:1349-1350.
    >> Share

  90. IKEGAMI S, Nakamura M, Honda T, Kawashima H, et al
    Letter: 1-kestose, the smallest fructooligosaccharide component, protection for mild to moderate ulcerative colitis patients-authors' reply.
    Aliment Pharmacol Ther. 2023;57:1351-1352.
    >> Share

  91. HANZEL J, Drobne D
    Editorial: golimumab dosing intensification effective in ulcerative colitis with no need for therapeutic drug monitoring.
    Aliment Pharmacol Ther. 2023;57:1469-1470.
    >> Share

  92. SETHI S, Kumar A, Dias S, Blackwell J, et al
    Editorial: proactive anti-TNF drug monitoring in IBD-Ready for the prime time? Authors' reply.
    Aliment Pharmacol Ther. 2023;57:1455-1456.
    >> Share

  93. FUMERY M, Roblin X
    Editorial: golimumab dosing intensification effective in ulcerative colitis with no need for therapeutic drug monitoring-author's reply.
    Aliment Pharmacol Ther. 2023;57:1471-1472.
    >> Share

  94. ROBLIN X, Nancey S
    Editorial: proactive anti-TNF drug monitoring in IBD-Ready for prime time?
    Aliment Pharmacol Ther. 2023;57:1453-1454.
    >> Share

  95. POLLOK RC, Jayasooriya N, Baillie S, Blackwell J, et al
    Letter: delays to diagnosis of IBD-Challenges requiring a systematic approach. Authors' reply.
    Aliment Pharmacol Ther. 2023;57:1479.
    >> Share

  96. CHANG HC, Gau SY
    Letter: histologic disease activity and colorectal neoplasia risk.
    Aliment Pharmacol Ther. 2023;57:1480.
    >> Share

  97. LUCAS S, Chauhan A, Garg M
    Letter: delays to diagnosis of IBD-Challenges requiring a systematic approach.
    Aliment Pharmacol Ther. 2023;57:1477-1478.
    >> Share

    May 2023
  98. ATIA O, Klomberg RCW, de Ridder L, Kemos P, et al
    Validation of predictive models for disease outcomes in paediatric ulcerative colitis: A multicentre prospective inception cohort.
    Aliment Pharmacol Ther. 2023 May 29. doi: 10.1111/apt.17544.
    >> Share

  99. KREIJNE JE, Goetgebuer RL, Erler NS, De Boer NK, et al
    Cumulative exposure to immunomodulators increases risk of cervical neoplasia in women with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2023 May 23. doi: 10.1111/apt.17555.
    >> Share

  100. YANAI H, Salomon N, Lahat A, Ungar B, et al
    Real-world experience with Curcumin-QingDai combination for patients with active ulcerative colitis: A retrospective multicentre cohort study.
    Aliment Pharmacol Ther. 2023 May 8. doi: 10.1111/apt.17538.
    >> Share

  101. OH SJ, Kim HJ, Lee CK
    A dose-dependent increase in the risk of inflammatory bowel disease after exposure to broad-spectrum antibiotics: A national population study in Korea.
    Aliment Pharmacol Ther. 2023 May 8. doi: 10.1111/apt.17542.
    >> Share

  102. CHEN J, Ruan X, Yuan S, Theodoratou E, et al
    Editorial: in search of environmental risk factors of Crohn's disease and ulcerative colitis with mendelian randomisation-authors' reply.
    Aliment Pharmacol Ther. 2023;57:1034-1035.
    >> Share

  103. VAN RULER O, Arkenbosch JHC, van der Woude CJ
    Editorial: Heal thyself-Autologous therapy for perianal Crohn's disease. Authors' reply.
    Aliment Pharmacol Ther. 2023;57:1030-1031.
    >> Share

  104. BURISCH J
    Editorial: Why are patients with Crohn's disease still treated with 5-aminosalicylates?
    Aliment Pharmacol Ther. 2023;57:1044-1045.
    >> Share

  105. DART RJ
    Editorial: Heal thyself-Autologous therapy for perianal Crohn's disease.
    Aliment Pharmacol Ther. 2023;57:1028-1029.
    >> Share

  106. MEYER A, Amiot A, Carbonnel F
    Editorial: in search of environmental risk factors of Crohn's disease and ulcerative colitis with mendelian randomisation.
    Aliment Pharmacol Ther. 2023;57:1032-1033.
    >> Share

  107. CHEN J, Ruan X, Yuan S, Theodoratou E, et al
    Letter: disentangling the role of redox-active compounds in the development of inflammatory bowel diseases-moving towards causal associations. Authors' reply.
    Aliment Pharmacol Ther. 2023;57:1048-1049.
    >> Share

  108. GEERTSEMA S, van Goor H, Dijkstra G, Faber KN, et al
    Letter: disentangling the role of redox-active compounds in the development of inflammatory bowel diseases - moving towards causal associations.
    Aliment Pharmacol Ther. 2023;57:1046-1047.
    >> Share

  109. SONNENBERG A, Genta RM
    Editorial: concurrence of coeliac disease with inflammatory bowel disease - is big data the final arbiter? Authors' reply.
    Aliment Pharmacol Ther. 2023;57:1155-1156.
    >> Share

  110. SZIGETI R, Krishna M, Kellermayer R
    Letter: fulminant-onset complicated inflammatory bowel disease (IBD)-a unique subtype?
    Aliment Pharmacol Ther. 2023;57:1192-1193.
    >> Share

  111. POLLOK RC, Baillie S, Jayasooriya N, Blackwell J, et al
    Letter: diagnostic delay in inflammatory bowel disease-Authors' reply.
    Aliment Pharmacol Ther. 2023;57:1205-1206.
    >> Share

  112. ATIA O, Goren I, Yanai H
    Letter: 5-aminosalicylate maintenance treatment in mild Crohn's disease-authors' reply.
    Aliment Pharmacol Ther. 2023;57:1184-1185.
    >> Share

  113. ANDERSON RP
    Editorial: concurrence of coeliac disease with inflammatory bowel disease - is big data the final arbiter?
    Aliment Pharmacol Ther. 2023;57:1153-1154.
    >> Share

  114. TASSONE D, Gilmore R, Lee T, Ding NS, et al
    Letter: diagnostic delay in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2023;57:1203-1204.
    >> Share

  115. JAYASOORIYA N, Saxena S, Pollok RC
    Letter: fulminant onset complicated inflammatory bowel disease (IBD) - a unique subtype? Authors' reply.
    Aliment Pharmacol Ther. 2023;57:1194-1195.
    >> Share

  116. CHANG HC, Gau SY
    Letter: 5-aminosalicylate maintenance treatment in mild Crohn's disease.
    Aliment Pharmacol Ther. 2023;57:1183.
    >> Share

    April 2023
  117. CASANOVA MJ, Nantes O, Varela P, Vela-Gonzalez M, et al
    Real-world outcomes of switching from adalimumab originator to adalimumab biosimilar in patients with inflammatory bowel disease: The ADA-SWITCH study.
    Aliment Pharmacol Ther. 2023 Apr 23. doi: 10.1111/apt.17525.
    >> Share

  118. NORGARD BM, Zegers FD, Knudsen T, Kjeldsen J, et al
    Patients with elderly onset inflammatory bowel disease have a decreased chance of initiation of all types of medications and increased risk of surgeries-A nationwide cohort study.
    Aliment Pharmacol Ther. 2023 Apr 20. doi: 10.1111/apt.17520.
    >> Share

  119. BOKEMEYER B, Plachta-Danielzik S, di Giuseppe R, Helwig U, et al
    Evaluation of a downstaging, bidirectional version of the Montreal classification of Crohn's disease: Analysis of 5-year follow-up data from the prospective BioCrohn study.
    Aliment Pharmacol Ther. 2023 Apr 13. doi: 10.1111/apt.17512.
    >> Share

  120. GOLD SL, Raman M, Sands BE, Ungaro R, et al
    Review article: Putting some muscle into sarcopenia-the pathogenesis, assessment and clinical impact of muscle loss in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2023 Apr 13. doi: 10.1111/apt.17498.
    >> Share

  121. OLIVERA PA, Lasa JS, Peretto G, Zuily S, et al
    Review article: Risk of cardiovascular events in patients with inflammatory bowel disease receiving small molecule drugs.
    Aliment Pharmacol Ther. 2023 Apr 10. doi: 10.1111/apt.17509.
    >> Share

  122. VASANT DH, Nigam GB, Bate S, Hamdy S, et al
    The prevalence and burden of Rome IV faecal incontinence in ulcerative colitis: A cross-sectional study.
    Aliment Pharmacol Ther. 2023 Apr 3. doi: 10.1111/apt.17502.
    >> Share

  123. GUPTA A, Kedia S, Ahuja V
    Letter: trial of antitubercular therapy for diagnosing Crohn's disease in LMICs-double whammy?
    Aliment Pharmacol Ther. 2023;57:815-816.
    >> Share

  124. SPEEDY AP, Wall CL
    Editorial: Interdisciplinary and multidisciplinary approach to malnutrition in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2023;57:907-908.
    >> Share

    March 2023
  125. WOLF T, Lewis A, Beaugerie L, Svrcek M, et al
    Risk of colorectal neoplasia according to histologic disease activity in patients with inflammatory bowel disease and colonic post-inflammatory polyps.
    Aliment Pharmacol Ther. 2023 Mar 31. doi: 10.1111/apt.17495.
    >> Share

  126. CALDERA F, Spaulding AC, Borah B, Moriarty J, et al
    Cost-effectiveness of an adjuvanted recombinant zoster vaccine in adults with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2023 Mar 10. doi: 10.1111/apt.17454.
    >> Share

  127. ATIA O, Goren I, Fischler TS, Weisband YL, et al
    5-aminosalicylate maintenance is not superior to no maintenance in patients with newly diagnosed Crohn's disease-A nationwide cohort study.
    Aliment Pharmacol Ther. 2023 Mar 9. doi: 10.1111/apt.17419.
    >> Share

  128. MELTON SL, Taylor KM, Gibson PR, Halmos EP, et al
    Review article: Mechanisms underlying the effectiveness of exclusive enteral nutrition in Crohn's disease.
    Aliment Pharmacol Ther. 2023 Mar 9. doi: 10.1111/apt.17451.
    >> Share

  129. CHANG HC, Gau SY
    Letter: sleep duration and the incidence of inflammatory bowel disease.
    Aliment Pharmacol Ther. 2023;57:595-596.
    >> Share

  130. COLMAN RJ, Minar P
    Editorial: achievements and unresolved questions in improving the pharmacokinetics of vedolizumab in adolescents with inflammatory bowel disease-authors' reply.
    Aliment Pharmacol Ther. 2023;57:567-568.
    >> Share

  131. HORSFALL E, Irwin J
    Editorial: inflammatory bowel disease and sleep.
    Aliment Pharmacol Ther. 2023;57:573-574.
    >> Share

  132. CORTESI PA, Fiorino G, Mantovani LG, Danese S, et al
    Editorial: treat-to-target in ulcerative colitis clinical management-a small price to pay? Authors' reply.
    Aliment Pharmacol Ther. 2023;57:571-572.
    >> Share

  133. BARBER GE, Gubatan J
    Editorial: treat-to-target in ulcerative colitis clinical management-a small price to pay?
    Aliment Pharmacol Ther. 2023;57:569-570.
    >> Share

  134. YUAN S, Chen J, Li X
    Editorial: IBD and sleep-authors' reply.
    Aliment Pharmacol Ther. 2023;57:575-576.
    >> Share

  135. VUIJK SA, de Ridder L
    Editorial: achievements and unresolved questions in improving the pharmacokinetics of vedolizumab in adolescents with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2023;57:565-566.
    >> Share

  136. PEYRIN-BIROULET L, Ghosh S, Lee SD, Lee WJ, et al
    Effect of risankizumab on health-related quality of life in patients with Crohn's disease: results from phase 3 MOTIVATE, ADVANCE and FORTIFY clinical trials.
    Aliment Pharmacol Ther. 2023;57:496-508.
    >> Share

  137. BUISSON A
    Editorial: real-world evidence of tofacitinib and vedolizumab in ulcerative colitis-are we one step closer to better positioning therapies after anti-TNF failure? Authors' reply.
    Aliment Pharmacol Ther. 2023;57:735-736.
    >> Share

  138. VOLKERS A, Straatmijer T, Duijvestein M, Lowenberg M, et al
    Letter: tricky reactions to switch back from subcutaneous to intravenous vedolizumab in inflammatory bowel disease patients-authors' reply.
    Aliment Pharmacol Ther. 2023;57:743-744.
    >> Share

  139. ERNEST-SUAREZ K, Lu C
    Editorial: real-world evidence of tofacitinib and vedolizumab in ulcerative colitis-are we one step closer to better positioning therapies after anti-TNF failure?
    Aliment Pharmacol Ther. 2023;57:733-734.
    >> Share

  140. RICHARD N, Vuitton L, Fumery M
    Letter: tricky reactions to switch back from subcutaneous to intravenous vedolizumab in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2023;57:741-742.
    >> Share

    February 2023
  141. FUMERY M, Nancey S, Filippi J, Altwegg R, et al
    Effectiveness of golimumab intensification in ulcerative colitis: A multicentric prospective study.
    Aliment Pharmacol Ther. 2023 Feb 27. doi: 10.1111/apt.17421.
    >> Share

  142. REGEV S, Schwartz D, Sarid O, Goren G, et al
    Randomised clinical trial: Psychological intervention improves work productivity and daily activity by reducing abdominal pain and fatigue in Crohn's disease.
    Aliment Pharmacol Ther. 2023 Feb 2. doi: 10.1111/apt.17399.
    >> Share

  143. SONNENBERG A, Genta RM
    Case-control study of the concurrence of coeliac disease with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2023 Feb 2. doi: 10.1111/apt.17408.
    >> Share

  144. CHOWDHURY R, Kane SV
    Editorial: predictors of disease activity during pregnancy in women with inflammatory bowel disease-a Danish cohort study.
    Aliment Pharmacol Ther. 2023;57:349-350.
    >> Share

  145. VESTERGAARD T, Kelsen J, Julsgaard M
    Editorial: predictors of disease activity during pregnancy in women with inflammatory bowel disease - a Danish cohort study. Authors' reply.
    Aliment Pharmacol Ther. 2023;57:351-352.
    >> Share

    January 2023
  146. CHEN J, Ruan X, Yuan S, Deng M, et al
    Antioxidants, minerals and vitamins in relation to Crohn's disease and ulcerative colitis: A Mendelian randomization study.
    Aliment Pharmacol Ther. 2023 Jan 16. doi: 10.1111/apt.17392.
    >> Share

  147. TAXONERA C, Olivares D, Lopez-Garcia ON, Alba C, et al
    Meta-analysis: Real-world effectiveness and safety of ustekinumab in patients with ulcerative colitis.
    Aliment Pharmacol Ther. 2023 Jan 16. doi: 10.1111/apt.17386.
    >> Share

  148. KHAN N, Mahmud N, Patel M, Sundararajan R, et al
    Risk of severe and opportunistic infections and the impact of SARS-COV-2 on this risk in a nationwide cohort of patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2023 Jan 16. doi: 10.1111/apt.17393.
    >> Share

  149. IKEGAMI S, Nakamura M, Honda T, Yamamura T, et al
    Efficacy of 1-kestose supplementation in patients with mild to moderate ulcerative colitis: A randomised, double-blind, placebo-controlled pilot study.
    Aliment Pharmacol Ther. 2023 Jan 16. doi: 10.1111/apt.17387.
    >> Share

  150. DUA A, Corson M, Sauk JS, Jaffe N, et al
    Impact of malnutrition and nutrition support in hospitalised patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2023 Jan 13. doi: 10.1111/apt.17389.
    >> Share

  151. JAYASOORIYA N, Baillie S, Blackwell J, Bottle A, et al
    Systematic review with meta-analysis: Time to diagnosis and the impact of delayed diagnosis on clinical outcomes in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2023 Jan 10. doi: 10.1111/apt.17370.
    >> Share

  152. LAHARIE D, Riviere P
    Editorial: selecting therapy for ulcerative colitis-think a step ahead.
    Aliment Pharmacol Ther. 2023;57:161-162.
    >> Share

  153. WOELFEL S, Dutschler J, Konig M, Graf N, et al
    Systemic and T cell-associated responses to SARS-CoV-2 immunisation in gut inflammation (STAR SIGN study): effects of biologics on vaccination efficacy of the third dose of mRNA vaccines against SARS-CoV-2.
    Aliment Pharmacol Ther. 2023;57:103-116.
    >> Share

  154. REIJNTJES MA, de Voogd FAE, Buskens CJ, Gecse KB, et al
    Editorial: routine use of intestinal ultrasound in ulcerative colitis-are we missing the appendix? Authors' reply.
    Aliment Pharmacol Ther. 2023;57:255-256.
    >> Share

  155. SCRIBANO ML
    Editorial: shared decision-making intervention in patients with Crohn's disease-a personalised, patient-centred approach.
    Aliment Pharmacol Ther. 2023;57:263-264.
    >> Share

  156. ERNEST-SUAREZ K, Novak K
    Editorial: routine use of intestinal ultrasound in ulcerative colitis-are we missing the appendix?
    Aliment Pharmacol Ther. 2023;57:253-254.
    >> Share

  157. LIWINSKI T, Hubener S, Henze L, Hubener P, et al
    A prospective pilot study of a gluten-free diet for primary sclerosing cholangitis and associated colitis.
    Aliment Pharmacol Ther. 2023;57:224-236.
    >> Share

    December 2022
  158. DIN S, Selinger CP, Black CJ, Ford AC, et al
    Systematic review with network meta-analysis: Risk of Herpes zoster with biological therapies and small molecules in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2022 Dec 31. doi: 10.1111/apt.17379.
    >> Share

  159. ARKENBOSCH JHC, van Ruler O, Dwarkasing RS, Fuhler GM, et al
    Stromal vascular fraction with platelet-rich plasma injection during surgery is feasible and safe in treatment-refractory perianal fistulising Crohn's disease: A pilot study.
    Aliment Pharmacol Ther. 2022 Dec 26. doi: 10.1111/apt.17347.
    >> Share

  160. FUMERY M, Defrance A, Roblin X, Altwegg R, et al
    Effectiveness and safety of risankizumab induction therapy for 100 patients with Crohn's disease: A GETAID multicentre cohort study.
    Aliment Pharmacol Ther. 2022 Dec 19. doi: 10.1111/apt.17358.
    >> Share

  161. VESTERGAARD T, Julsgaard M, Rosok JF, Vestergaard SV, et al
    Predictors of disease activity during pregnancy in women with inflammatory bowel disease-a Danish cohort study.
    Aliment Pharmacol Ther. 2022 Dec 14. doi: 10.1111/apt.17348.
    >> Share

  162. SETHI S, Dias S, Kumar A, Blackwell J, et al
    Meta-analysis: The efficacy of therapeutic drug monitoring of anti-TNF-therapy in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2022 Dec 9. doi: 10.1111/apt.17313.
    >> Share

  163. VUIJK SA, de Ridder L
    Editorial: implications and future perspectives of the increase in biologics use in paediatric inflammatory bowel disease.
    Aliment Pharmacol Ther. 2022;56.
    >> Share

  164. KULYK A, Shafer LA, Graff LA, Stone J, et al
    Urgency for bowel movements is a highly discriminatory symptom of active disease in persons with IBD (the Manitoba Living with IBD study).
    Aliment Pharmacol Ther. 2022;56.
    >> Share

    November 2022
  165. BUISSON A, Nachury M, Guilmoteau T, Altwegg R, et al
    Real-world comparison of effectiveness between tofacitinib and vedolizumab in patients with ulcerative colitis exposed to at least one anti-TNF agent.
    Aliment Pharmacol Ther. 2022 Nov 19. doi: 10.1111/apt.17305.
    >> Share

  166. CORTESI PA, Fiorino G, Peyrin-Biroulet L, Mantovani LG, et al
    Non-invasive monitoring and treat-to-target approach are cost-effective in patients with mild-moderate ulcerative colitis.
    Aliment Pharmacol Ther. 2022 Nov 15. doi: 10.1111/apt.17261.
    >> Share

  167. ZISMAN-ILANI Y, Thompson KD, Siegel LS, Mackenzie T, et al
    Crohn's disease shared decision making intervention leads to more patients choosing combination therapy: a cluster randomised controlled trial.
    Aliment Pharmacol Ther. 2022 Nov 14. doi: 10.1111/apt.17286.
    >> Share

  168. YUAN S, Sun Y, Tan X, Geng J, et al
    Sleep duration and daytime napping in relation to incident inflammatory bowel disease: a prospective cohort study.
    Aliment Pharmacol Ther. 2022 Nov 9. doi: 10.1111/apt.17285.
    >> Share

  169. EVERHOV AH, Olen O
    Editorial: colorectal cancer in elderly-onset IBD-what is the risk? Authors' reply.
    Aliment Pharmacol Ther. 2022;56:1423-1424.
    >> Share

  170. WEISS A, Buchner AM
    Editorial: colorectal cancer in elderly-onset inflammatory bowel disease-what is the risk?
    Aliment Pharmacol Ther. 2022;56:1421-1422.
    >> Share

  171. LEE KE, Faye AS
    Letter: fighting the battle but losing the war-inflammatory bowel disease and venous thromboembolism. Authors' reply.
    Aliment Pharmacol Ther. 2022;56:1427-1428.
    >> Share

  172. SAHYOUN L, Dahiya DS, Cheng CI, Sultan K, et al
    Letter: fighting the battle but losing the war-inflammatory bowel disease and venous thromboembolism.
    Aliment Pharmacol Ther. 2022;56:1425-1426.
    >> Share

  173. BEZZIO C, Alimenti E, Saibeni S
    Letter: immune-mediated inflammatory diseases and inflammatory bowel disease-are we ready for a Copernican revolution?
    Aliment Pharmacol Ther. 2022;56:1429-1430.
    >> Share

  174. DAHL EK, Abed OK, Kjeldsen J, Donia M, et al
    Safety and efficacy of infliximab and corticosteroid therapy in checkpoint inhibitor-induced colitis.
    Aliment Pharmacol Ther. 2022;56:1370-1382.
    >> Share

  175. NORGARD BM, Friedman S, Kjeldsen J, Nielsen J, et al
    The safety of paternal and maternal use of 5-aminosalicylic acid during conception and pregnancy: a nationwide cohort study.
    Aliment Pharmacol Ther. 2022;56:1349-1360.
    >> Share

  176. RONNOW SAND J, Troelsen FS, Horvath-Puho E, Henderson VW, et al
    Letter: comedication use and dementia risk in patients with inflammatory bowel disease-authors' reply.
    Aliment Pharmacol Ther. 2022;56:1505-1506.
    >> Share

  177. CHANG HC, Gau SY
    Letter: comedication use and dementia risk in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2022;56:1503-1504.
    >> Share

  178. REIJNTJES MA, de Voogd FAE, Bemelman WA, Hompes R, et al
    Intestinal ultrasound detects an increased diameter and submucosal layer thickness in the appendix of patients with ulcerative colitis compared to healthy controls - a prospective cohort study.
    Aliment Pharmacol Ther. 2022 Nov 1. doi: 10.1111/apt.17267.
    >> Share

    October 2022
  179. COLMAN RJ, Mizuno T, Fukushima K, Haslam DB, et al
    Real world population pharmacokinetic study in children and young adults with inflammatory bowel disease discovers novel blood and stool microbial predictors of vedolizumab clearance.
    Aliment Pharmacol Ther. 2022 Oct 31. doi: 10.1111/apt.17277.
    >> Share

  180. STRAATMIJER T, van Schaik FDM, Bodelier AGL, Visschedijk M, et al
    Effectiveness and safety of tofacitinib for ulcerative colitis: two-year results of the ICC Registry.
    Aliment Pharmacol Ther. 2022 Oct 25. doi: 10.1111/apt.17248.
    >> Share

  181. SAIFUDDIN A, Kent AJ, Mehta SJ, Hicks LC, et al
    Treatment adaptations and outcomes of patients experiencing inflammatory bowel disease flares during the early COVID-19 pandemic: the PREPARE-IBD multicentre cohort study.
    Aliment Pharmacol Ther. 2022 Oct 5. doi: 10.1111/apt.17223.
    >> Share

  182. BURGESS CJ, Jackson R, Chalmers I, Russell RK, et al
    The inexorable increase of biological exposure in paediatric inflammatory bowel disease: a Scottish, population-based, longitudinal study.
    Aliment Pharmacol Ther. 2022 Oct 4. doi: 10.1111/apt.17217.
    >> Share

  183. BURISCH J
    Editorial: trends in the epidemiology of inflammatory bowel disease in Korea.
    Aliment Pharmacol Ther. 2022;56:1207-1208.
    >> Share

  184. BODGER K
    Editorial: rising rates of venous thromboembolism among hospitalised patients with inflammatory bowel disease in the USA.
    Aliment Pharmacol Ther. 2022;56:1211-1212.
    >> Share

  185. SHIM JO
    Editorial: trends in the epidemiology of inflammatory bowel disease in Korea - author's reply.
    Aliment Pharmacol Ther. 2022;56:1209-1210.
    >> Share

  186. LEE KE, Faye AS
    Editorial: rising rates of venous thromboembolism among hospitalised patients with inflammatory bowel disease in the USA-authors' reply.
    Aliment Pharmacol Ther. 2022;56:1213-1214.
    >> Share

  187. CHOI SY, Kim ES, Jeon TY, Lee YM, et al
    Transmural healing evaluated by magnetic resonance enterography in paediatric patients with Crohn's disease receiving maintenance treatment with biologics.
    Aliment Pharmacol Ther. 2022;56:1146-1156.
    >> Share

  188. SHIN A
    Editorial: natural history of irritable bowel syndrome in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2022;56:1300-1301.
    >> Share

  189. FAIRBRASS KM, Hamlin PJ, Gracie DJ, Ford AC, et al
    Editorial: natural history of irritable bowel syndrome in inflammatory bowel disease-authors' reply.
    Aliment Pharmacol Ther. 2022;56:1302-1303.
    >> Share

    September 2022
  190. AVNI-BIRON I, Mishael T, Zittan E, Livne-Margolin M, et al
    Ustekinumab during pregnancy in patients with inflammatory bowel disease: a prospective multicentre cohort study.
    Aliment Pharmacol Ther. 2022 Sep 27. doi: 10.1111/apt.17224.
    >> Share

  191. BLACK J, Sweeney L, Yuan Y, Singh H, et al
    Systematic review: the role of psychological stress in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2022 Sep 8. doi: 10.1111/apt.17202.
    >> Share

  192. ROSIOU K, Selinger CP
    Editorial: progress towards more comprehensively understanding the sources of corticosteroids for patients with inflammatory bowel disease-authors' reply.
    Aliment Pharmacol Ther. 2022;56:898-899.
    >> Share

  193. HAYDEK JP, Scott FI
    Editorial: progress towards more comprehensively understanding the sources of corticosteroids for patients with IBD.
    Aliment Pharmacol Ther. 2022;56:896-897.
    >> Share

  194. BERTANI L, Trico D
    Editorial: serum triiodothyronine-to-thyroxine (T3/T4) ratio as biomarker of response in IBD - an open issue.
    Aliment Pharmacol Ther. 2022;56:903-904.
    >> Share

  195. HUDSON AS, Wine E
    Editorial: further support for exclusive enteral nutrition in paediatric Crohn's disease.
    Aliment Pharmacol Ther. 2022;56:900-901.
    >> Share

  196. KANE S
    Editorial: paternal use of IBD therapies and risk of infant infection.
    Aliment Pharmacol Ther. 2022;56:902.
    >> Share

  197. LIN S, Chanchlani N, Carbery I, Janjua M, et al
    Understanding anti-TNF treatment failure: does serum triiodothyronine-to-thyroxine (T3/T4) ratio predict therapeutic outcome to anti-TNF therapies in biologic-naive patients with active luminal Crohn's disease?
    Aliment Pharmacol Ther. 2022;56:783-793.
    >> Share

  198. ATIA O, Pujol-Muncunill G, Navas-Lopez VM, Orlanski-Meyer E, et al
    Children included in randomised controlled trials of biologics in inflammatory bowel diseases do not represent the real-world patient mix.
    Aliment Pharmacol Ther. 2022;56:794-801.
    >> Share

  199. LIMA CCG, Peerani F
    Editorial: IBD and the risk of dementia - the jury is still out.
    Aliment Pharmacol Ther. 2022;56:1078-1079.
    >> Share

  200. LOPES EW, Khalili H
    Editorial: investigating the association between sweetened beverages and risk of inflammatory bowel disease.
    Aliment Pharmacol Ther. 2022;56:1086-1087.
    >> Share

  201. FU T, Wang X, Chen J
    Editorial: investigating the association between sweetened beverages and risk of inflammatory bowel disease-authors' reply.
    Aliment Pharmacol Ther. 2022;56:1088-1089.
    >> Share

  202. HENDERSON P
    Editorial: earning potential in paediatric-onset IBD-a complex interplay.
    Aliment Pharmacol Ther. 2022;56:1084-1085.
    >> Share

  203. ZHAO M, Lirhus S, Lordal M, Langholz E, et al
    Therapeutic management and outcomes in inflammatory bowel diseases, 2010 to 2017 in cohorts from Denmark, Sweden and Norway.
    Aliment Pharmacol Ther. 2022;56:989-1006.
    >> Share

  204. VOLKERS A, Straatmijer T, Duijvestein M, Sales A, et al
    Real-world experience of switching from intravenous to subcutaneous vedolizumab maintenance treatment for inflammatory bowel diseases.
    Aliment Pharmacol Ther. 2022;56:1044-1054.
    >> Share

    August 2022
  205. CHANCHLANI N, Lin S, Auth MK, Lee CL, et al
    Implications for sequencing of biologic therapy and choice of second anti-TNF in patients with inflammatory bowel disease: Results from the IMmunogenicity to Second Anti-TNF therapy (IMSAT) therapeutic drug monitoring study.
    Aliment Pharmacol Ther. 2022 Aug 29. doi: 10.1111/apt.17170.
    >> Share

  206. FAIRBRASS KM, Hamlin PJ, Gracie DJ, Ford AC, et al
    Natural history and impact of irritable bowel syndrome-type symptoms in inflammatory bowel disease during 6 years of longitudinal follow-up.
    Aliment Pharmacol Ther. 2022 Aug 22. doi: 10.1111/apt.17193.
    >> Share

  207. IRVING PM, Leung Y, Dubinsky MC
    Review article: guide to tofacitinib dosing in patients with ulcerative colitis.
    Aliment Pharmacol Ther. 2022 Aug 22. doi: 10.1111/apt.17185.
    >> Share

  208. MALMBORG P, Everhov AH, Soderling J, Ludvigsson JF, et al
    Earnings during adulthood in patients with childhood-onset inflammatory bowel disease: A nationwide population-based cohort study.
    Aliment Pharmacol Ther. 2022 Aug 2. doi: 10.1111/apt.17148.
    >> Share

  209. EVERHOV AH, Erichsen R, Jaras J, Pedersen L, et al
    Colorectal cancer in elderly-onset inflammatory bowel disease: A 1969-2017 Scandinavian register-based cohort study.
    Aliment Pharmacol Ther. 2022 Aug 2. doi: 10.1111/apt.17175.
    >> Share

  210. SOHOULI MH, Fatahi S, Farahmand F, Alimadadi H, et al
    Meta-analysis: efficacy of exclusive enteral nutrition as induction therapy on disease activity index, inflammation and growth factors in paediatric Crohn's disease.
    Aliment Pharmacol Ther. 2022;56:384-395.
    >> Share

  211. TAXONERA C
    Editorial: golimumab thresholds to achieve stringent medium- and long-term therapeutic outcomes in patients with ulcerative colitis-Author's reply.
    Aliment Pharmacol Ther. 2022;56:737-738.
    >> Share

  212. HAWTHORNE AB, Lamb CA
    Editorial: quality assessment in IBD in high resource countries can lead to quality improvement clues for IBD management worldwide-authors' reply.
    Aliment Pharmacol Ther. 2022;56:743.
    >> Share

  213. MANTZARIS GJ, Papamichael K
    Editorial: golimumab thresholds to achieve stringent medium- and long-term therapeutic outcomes in patients with ulcerative colitis.
    Aliment Pharmacol Ther. 2022;56:735-736.
    >> Share

  214. PUGLIESE D, Privitera G, Armuzzi A
    Editorial: effectiveness and safety of vedolizumab in a matched cohort of elderly and non-elderly patients with inflammatory bowel disease-the IG-IBD LIVE study. Authors' reply.
    Aliment Pharmacol Ther. 2022;56:733-734.
    >> Share

  215. BERNSTEIN CN
    Editorial: quality assessment in IBD in high-resource countries can lead to quality improvement clues for IBD management worldwide.
    Aliment Pharmacol Ther. 2022;56:741-742.
    >> Share

  216. KEEFER L, Shapiro MJ
    Editorial: measuring disease severity in inflammatory bowel disease-the whole is greater than the sum of its parts.
    Aliment Pharmacol Ther. 2022;56:744-745.
    >> Share

  217. LEE H, Khan N
    Editorial: effectiveness and safety of vedolizumab in a matched cohort of elderly and non-elderly patients with inflammatory bowel disease - the IG-IBD LIVE study.
    Aliment Pharmacol Ther. 2022;56:731-732.
    >> Share

  218. GOLD SL, Raman M
    Editorial: a formula shake each day keeps the complications away - the tolerability and effect of orally-delivered enteral nutrition in improving post-operative outcomes in patients with Crohn's disease.
    Aliment Pharmacol Ther. 2022;56:739-740.
    >> Share

  219. SWAMINATHAN A, Mules TC, Gearry RB
    Editorial: measuring disease severity in inflammatory bowel disease-the whole is greater than the sum of its parts. Authors' reply.
    Aliment Pharmacol Ther. 2022;56:746-747.
    >> Share

  220. MEADE S, Patel KV, Luber RP, O'Hanlon D, et al
    A retrospective cohort study: pre-operative oral enteral nutritional optimisation for Crohn's disease in a UK tertiary IBD centre.
    Aliment Pharmacol Ther. 2022;56:646-663.
    >> Share

  221. BOURGONJE AR, Alexdottir MS, Otten AT, Loveikyte R, et al
    Serological biomarkers of type I, III and IV collagen turnover are associated with the presence and future progression of stricturing and penetrating Crohn's disease.
    Aliment Pharmacol Ther. 2022;56:675-693.
    >> Share

    July 2022
  222. FAYE AS, Lee KE, Dodson J, Chodosh J, et al
    Increasing rates of venous thromboembolism among hospitalised patients with inflammatory bowel disease: a nationwide analysis.
    Aliment Pharmacol Ther. 2022 Jul 25. doi: 10.1111/apt.17162.
    >> Share

  223. FU T, Chen H, Chen X, Sun Y, et al
    Sugar-sweetened beverages, artificially sweetened beverages and natural juices and risk of inflammatory bowel disease: a cohort study of 121,490 participants.
    Aliment Pharmacol Ther. 2022 Jul 18. doi: 10.1111/apt.17149.
    >> Share

  224. REZAZADEH ARDABILI A, Jeuring S, Mujagic Z, Oostenbrug L, et al
    Classic drugs in the time of new drugs: Real-world, long-term outcomes of thiopurine monotherapy in 1016 patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2022 Jul 6. doi: 10.1111/apt.17128.
    >> Share

  225. CHOE YJ, Han K, Shim JO
    Treatment patterns of anti-tumour necrosis factor-alpha and prognosis of paediatric and adult-onset inflammatory bowel disease in Korea: a nationwide population-based study.
    Aliment Pharmacol Ther. 2022 Jul 6. doi: 10.1111/apt.17125.
    >> Share

  226. BIRON A, Beaugerie L, Chazouilleres O, Kirchgesner J, et al
    Impact of thiopurines and tumour necrosis factor antagonists on primary sclerosing cholangitis outcomes in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2022 Jul 4. doi: 10.1111/apt.17123.
    >> Share

  227. SAND JR, Troelsen FS, Horvath-Puho E, Henderson VW, et al
    Risk of dementia in patients with inflammatory bowel disease: a Danish population-based study.
    Aliment Pharmacol Ther. 2022 Jul 3. doi: 10.1111/apt.17119.
    >> Share

  228. QUINN KP, Busciglio IA, Burton DD, Inoue A, et al
    Letter: normalizing the ileoanal pouch-more than a one-step technique. Authors' reply.
    Aliment Pharmacol Ther. 2022;56:176-177.
    >> Share

  229. WEST J, Card TR, Crooks CJ
    Editorial: seeing the light at the end of gastroscope - complications after elective procedures are ready for NICE, bright decision aid tools - authors' reply.
    Aliment Pharmacol Ther. 2022;56:157.
    >> Share

  230. HADI Y, Kochhar GS
    Letter: paying attention to the comorbidities or extraintestinal complications in patients with inflammatory bowel disease during the COVID-19 pandemic-authors' reply.
    Aliment Pharmacol Ther. 2022;56:178.
    >> Share

  231. LO SW, Garg M, Segal JP
    Letter: normalising the ileoanal pouch-more than a one-step technique.
    Aliment Pharmacol Ther. 2022;56:174-175.
    >> Share

  232. BHURWAL A, Mutneja H, Seril D
    Editorial: COVID-19 vaccines are safe and effective in patients with inflammatory bowel disease-but many unanswered questions remain. Authors' reply.
    Aliment Pharmacol Ther. 2022;56:164-165.
    >> Share

  233. BENCHIMOL EI, Kuenzig ME
    Editorial: COVID-19 vaccines are safe and effective in patients with inflammatory bowel disease-but many unanswered questions remain.
    Aliment Pharmacol Ther. 2022;56:162-163.
    >> Share

  234. HADI Y, Kochhar GS
    Letter: the effect of anti-COVID-19 treatment on the outcome of patients with inflammatory bowel disease-authors' reply.
    Aliment Pharmacol Ther. 2022;56:179.
    >> Share

  235. FEHILY SR, Al-Ani AH, Abdelmalak J, Rentch C, et al
    Review article: latent tuberculosis in patients with inflammatory bowel diseases receiving immunosuppression-risks, screening, diagnosis and management.
    Aliment Pharmacol Ther. 2022;56:6-27.
    >> Share

  236. VAUGHAN R, Tjandra D, Patwardhan A, Mingos N, et al
    Toward transmural healing: Sonographic healing is associated with improved long-term outcomes in patients with Crohn's disease.
    Aliment Pharmacol Ther. 2022;56:84-94.
    >> Share

  237. LYONS M, Derikx LAAP, Fulforth J, McCall S, et al
    Patterns of emergency admission for IBD patients over the last 10 years in Lothian, Scotland: a retrospective prevalent cohort analysis.
    Aliment Pharmacol Ther. 2022;56:67-76.
    >> Share

  238. ROBLIN X, Veyrard P, Bastide L, Berger AE, et al
    Subcutaneous injection of infliximab CT-P13 results in stable drug levels within 14-day treatment cycle in Crohn's disease.
    Aliment Pharmacol Ther. 2022;56:77-83.
    >> Share

  239. MASSIRONI S, Vigano C, Danese S
    Letter: pancreatic involvement in inflammatory bowel disease-authors' reply.
    Aliment Pharmacol Ther. 2022;56:371.
    >> Share

  240. DAI C, Huang YH
    Letter: pancreatic involvement in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2022;56:370.
    >> Share

  241. SOLITANO V, Armuzzi A
    Editorial: STAT3 phosphorylation for tofacitinib monitoring in ulcerative colitis-a step towards precision medicine?
    Aliment Pharmacol Ther. 2022;56:347-348.
    >> Share

  242. FRIEDMAN S
    Editorial: measuring fertility in men with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2022;56:345-346.
    >> Share

  243. GILL M, Majumdar A
    Editorial: optimising hepatitis B vaccine response in inflammatory bowel disease-time to get some skin in the game.
    Aliment Pharmacol Ther. 2022;56:353-354.
    >> Share

  244. KO KL, Hung IF, Leung WK
    Editorial: optimising hepatitis B vaccine response in inflammatory bowel disease-time to get some skin in the game. Authors' reply.
    Aliment Pharmacol Ther. 2022;56:355-356.
    >> Share

  245. MADSEN GR, Wilkens R, Boysen T, Burisch J, et al
    The knowledge and skills needed to perform intestinal ultrasound for inflammatory bowel diseases-an international Delphi consensus survey.
    Aliment Pharmacol Ther. 2022;56:263-270.
    >> Share

  246. PUGLIESE D, Privitera G, Crispino F, Mezzina N, et al
    Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the IG-IBD LIVE study.
    Aliment Pharmacol Ther. 2022;56:95-109.
    >> Share

    June 2022
  247. UMAR N, King D, Chandan JS, Bhala N, et al
    The association between inflammatory bowel disease and mental ill health: A retrospective cohort study using data from UK primary care.
    Aliment Pharmacol Ther. 2022 Jun 30. doi: 10.1111/apt.17110.
    >> Share

  248. FRIEDMAN S, Garvik OS, Nielsen J, Norgard BM, et al
    Paternal use of medications for inflammatory bowel disease and the risk of hospital-diagnosed infections in the offspring: A nationwide cohort study.
    Aliment Pharmacol Ther. 2022 Jun 30. doi: 10.1111/apt.17113.
    >> Share

  249. YUAN WQ, Li F, Yang LC, Yang ZL, et al
    Letter: paying attention to the comorbidities or extraintestinal complications in patients with inflammatory bowel disease during the COVID-19 pandemic.
    Aliment Pharmacol Ther. 2022;55:1464-1465.
    >> Share

  250. WANG CY, Lai CC
    Letter: the effect of anti-COVID-19 treatment on the outcome of patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2022;55:1462-1463.
    >> Share

  251. QUINN KP, Busciglio IA, Burton DD, Inoue A, et al
    Defining normal pouch function in patients with ileal pouch-anal anastomosis: a pilot study.
    Aliment Pharmacol Ther. 2022;55:1560-1568.
    >> Share

  252. HAWTHORNE AB, Glatter J, Blackwell J, Ainley R, et al
    Inflammatory bowel disease patient-reported quality assessment should drive service improvement: A national survey of UK IBD units and patients.
    Aliment Pharmacol Ther. 2022 Jun 1. doi: 10.1111/apt.17042.
    >> Share

    May 2022
  253. SWAMINATHAN A, Fan D, Borichevsky GM, Mules TC, et al
    The disease severity index for inflammatory bowel disease is associated with psychological symptoms, quality of life and predicts a more complicated disease course.
    Aliment Pharmacol Ther. 2022 May 27. doi: 10.1111/apt.17058.
    >> Share

  254. ROSIOU K, Carbonell J, Dolby V, Monfared N, et al
    Sources of excess steroid prescriptions and clinical adverse outcomes associated with steroid excess in patients with inflammatory bowel disease: The Leeds IBD Steroids study.
    Aliment Pharmacol Ther. 2022 May 24. doi: 10.1111/apt.17039.
    >> Share

  255. DRUVEFORS E, Andersson RE, Hammar U, Landerholm K, et al
    Minor impact on fertility in men with inflammatory bowel disease: A National Cohort Study from Sweden.
    Aliment Pharmacol Ther. 2022 May 22. doi: 10.1111/apt.16984.
    >> Share

  256. KO KL, Lam YF, Cheung KS, Hung IF, et al
    Clinical trial: intra-dermal hepatitis B vaccination with topical imiquimod versus intra-muscular hepatitis B vaccination in inflammatory bowel disease patients.
    Aliment Pharmacol Ther. 2022 May 11. doi: 10.1111/apt.16970.
    >> Share

  257. TAXONERA C, Fernandez-Acenero MJ, Olivares D, Calvo M, et al
    Association of golimumab trough concentrations during maintenance with clinical, biological, endoscopic and histologic remission in patients with ulcerative colitis.
    Aliment Pharmacol Ther. 2022 May 4. doi: 10.1111/apt.16964.
    >> Share

  258. MASSIRONI S, Fanetti I, Vigano C, Pirola L, et al
    Systematic review-Pancreatic involvement in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2022 May 3. doi: 10.1111/apt.16949.
    >> Share

  259. FALLOON K, Cohen B, Rieder F
    Editorial: shedding new light on extraintestinal manifestations in inflammatory bowel disease-authors' reply.
    Aliment Pharmacol Ther. 2022;55:1208-1209.
    >> Share

  260. HADI Y, Kochhar GS
    Letter: association between COVID-19 and inflammatory bowel disease-Authors' reply.
    Aliment Pharmacol Ther. 2022;55:1228-1229.
    >> Share

  261. KOKKOTIS G, Kitsou K, Bamias G
    Letter: COVID-19 outcomes and anti-TNF treatments-comprehensive evidence matters. Authors' reply.
    Aliment Pharmacol Ther. 2022;55:1235-1236.
    >> Share

  262. ARDALAN ZS, Friedman AB
    Editorial: the importance of utilising gastrointestinal ultrasound via transperineal approach in ulcerative colitis-an accurate early predictor of response to treatment.
    Aliment Pharmacol Ther. 2022;55:1202-1203.
    >> Share

  263. GUILLO L, Peyrin-Biroulet L, Danese S
    Editorial: shedding new light on extraintestinal manifestations in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2022;55:1206-1207.
    >> Share

  264. BURISCH J, Langholz E, Munkholm P
    Letter: the clinical course of Crohn's disease-the Sicilian experience. Authors' reply.
    Aliment Pharmacol Ther. 2022;55:1239-1240.
    >> Share

  265. CHEN HY, Wang SI, Chang R, Wei JC, et al
    Letter: association between COVID-19 and inflammatory bowel disease.
    Aliment Pharmacol Ther. 2022;55:1226-1227.
    >> Share

  266. DEMARZO MG, Viola A, Picci A, Fries W, et al
    Letter: the clinical course of Crohn's disease-the Sicilian experience.
    Aliment Pharmacol Ther. 2022;55:1237-1238.
    >> Share

  267. SAGAMI S, Kobayashi T
    Editorial: the importance of utilising gastrointestinal ultrasound via transperineal approach in ulcerative colitis-an accurate early predictor of response to treatment. Authors' reply.
    Aliment Pharmacol Ther. 2022;55:1204-1205.
    >> Share

  268. BACHOUR SP, Shah RS, Lyu R, Rieder F, et al
    Mild neoterminal ileal post-operative recurrence of Crohn's disease conveys higher risk for severe endoscopic disease progression than isolated anastomotic lesions.
    Aliment Pharmacol Ther. 2022;55:1139-1150.
    >> Share

  269. WONG ECL, Dulai PS, Marshall JK, Jairath V, et al
    Resolution of dominant patient-reported outcome at end of induction predicts clinical and endoscopic remission in Crohn's disease.
    Aliment Pharmacol Ther. 2022;55:1151-1159.
    >> Share

  270. WANG J, Goren I, Rieder F
    Letter: the sphingosine 1 phosphate/sphingosine 1 phosphate receptor axis-a unique therapeutic target in inflammatory bowel disease. Authors' reply.
    Aliment Pharmacol Ther. 2022;55:1360.
    >> Share

  271. FERNANDES RG, Radford-Smith G
    Editorial: is older-onset ulcerative colitis more severe or less aggressively managed?
    Aliment Pharmacol Ther. 2022;55:1350-1351.
    >> Share

  272. RADEKE HH, Stein J
    Letter: the sphingosine 1 phosphate/sphingosine 1 phosphate receptor axis-a unique therapeutic target in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2022;55:1359.
    >> Share

  273. OKABAYASHI S, Yamazaki H, Matsuoka K, Yamamoto Y, et al
    Editorial: is older-onset ulcerative colitis more severe or less aggressively managed? Authors' reply.
    Aliment Pharmacol Ther. 2022;55:1352-1353.
    >> Share

  274. KUMAR P, Vuyyuru SK, Kedia S, Ahuja V, et al
    Editorial: choosing the optimal screening method for latent TB in patients with IBD commencing anti-TNF-therapy-authors' reply.
    Aliment Pharmacol Ther. 2022;55:1348-1349.
    >> Share

  275. LOVATT J, Selinger CP
    Editorial: choosing the optimal screening method for latent TB in patients with IBD commencing anti-TNF therapy.
    Aliment Pharmacol Ther. 2022;55:1346-1347.
    >> Share

    April 2022
  276. VERSTOCKT B, Volk V, Jaeckel C, Alsoud D, et al
    Longitudinal monitoring of STAT3 phosphorylation and histologic outcome of tofacitinib therapy in patients with ulcerative colitis.
    Aliment Pharmacol Ther. 2022 Apr 28. doi: 10.1111/apt.16955.
    >> Share

  277. VANDE CASTEELE N, Sandborn WJ, Feagan BG, Vermeire S, et al
    Real-world multicentre observational study including population pharmacokinetic modelling to evaluate the exposure-response relationship of vedolizumab in inflammatory bowel disease: ERELATE Study.
    Aliment Pharmacol Ther. 2022 Apr 27. doi: 10.1111/apt.16937.
    >> Share

  278. BERGQVIST V, Holmgren J, Klintman D, Marsal J, et al
    Real-world data on switching from intravenous to subcutaneous vedolizumab treatment in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2022 Apr 25. doi: 10.1111/apt.16927.
    >> Share

  279. HALFVARSON JF, Ludvigsson JF, Bresso F, Askling J, et al
    Age determines the risk of familial inflammatory bowel disease-A nationwide study.
    Aliment Pharmacol Ther. 2022 Apr 22. doi: 10.1111/apt.16938.
    >> Share

  280. MOENS A, Sadat Seyed Tabib N, Ballet V, Sabino J, et al
    Safety of sequential biological therapy in inflammatory bowel disease: results from a tertiary referral Centre.
    Aliment Pharmacol Ther. 2022 Apr 20. doi: 10.1111/apt.16928.
    >> Share

  281. KHALILI H, Casey K
    Letter: risk of inflammatory bowel disease is related to alcohol consumption as well as ACEIs and ARBs-authors' reply.
    Aliment Pharmacol Ther. 2022;55:884.
    >> Share

  282. YIN JQ, Wang BQ, Chen ZB, He HD, et al
    Letter: risk of inflammatory bowel disease is related to alcohol consumption as well as ACEIs and ARBs.
    Aliment Pharmacol Ther. 2022;55:882-883.
    >> Share

  283. MUNGMUNPUNTIPANTIP R, Wiwanitkit V
    Letter: inflammatory bowel disease services during the Covid-19 pandemic.
    Aliment Pharmacol Ther. 2022;55:1063.
    >> Share

  284. DEPUTY M, Hart A, Faiz O
    Letter: inflammatory bowel disease services during the Covid-19 pandemic - authors' reply.
    Aliment Pharmacol Ther. 2022;55:1064.
    >> Share

  285. SELINGER CP, Lenti MV, De Silvestri A
    Letter: potential selection bias in real-world comparison of ustekinumab versus vedolizumab as a second-line treatment for Crohn's disease-authors' reply.
    Aliment Pharmacol Ther. 2022;55:1070-1071.
    >> Share

  286. ADOMI M, Ray A
    Letter: potential selection bias in the real-world comparison of ustekinumab versus vedolizumab as a second-line treatment for Crohn's disease.
    Aliment Pharmacol Ther. 2022;55:1069.
    >> Share

  287. KIM ES, Choi S, Choi SY, Park JH, et al
    NUDT15 intermediate metabolisers are associated with lower loss of response in paediatric Crohn's disease patients treated by combination treatment with infliximab and azathioprine.
    Aliment Pharmacol Ther. 2022;55:1008-1015.
    >> Share

  288. ALSOUD D, Verstockt B, Vermeire S
    Letter: immunogenicity is not the root cause for loss of response to anti-TNF agents in patients with IBD in TDM era.
    Aliment Pharmacol Ther. 2022;55:885-886.
    >> Share

  289. YANG H, Li B, Guo Q, Tang J, et al
    Systematic review with meta-analysis: loss of response and requirement of ustekinumab dose escalation in inflammatory bowel diseases.
    Aliment Pharmacol Ther. 2022;55:764-777.
    >> Share

  290. LENTI MV, Dolby V, Clark T, Hall V, et al
    A propensity score-matched, real-world comparison of ustekinumab vs vedolizumab as a second-line treatment for Crohn's disease. The Cross Pennine study II.
    Aliment Pharmacol Ther. 2022;55:856-866.
    >> Share

    March 2022
  291. BHURWAL A, Mutneja H, Bansal V, Goel A, et al
    Effectiveness and safety of SARS-CoV-2 vaccine in Inflammatory Bowel Disease patients: A systematic review, meta-analysis and meta-regression.
    Aliment Pharmacol Ther. 2022 Mar 30. doi: 10.1111/apt.16913.
    >> Share

  292. TOWNSEND CM, Lovegrove F, Khanna R, Wilson AS, et al
    Review article: paradoxical psoriasis as a consequence of tumour necrosis factor antagonists in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2022 Mar 21. doi: 10.1111/apt.16883.
    >> Share

  293. ZAMANI M, Alizadeh-Tabari S, Singh S, Loomba R, et al
    Meta-analysis: Prevalence of, and risk factors for, non-alcoholic fatty liver disease in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2022 Mar 11. doi: 10.1111/apt.16879.
    >> Share

  294. OKABAYASHI S, Yamazaki H, Tominaga K, Miura M, et al
    Lower effectiveness of intravenous steroid treatment for moderate-to-severe ulcerative colitis in hospitalised patients with older onset: A multicentre cohort study.
    Aliment Pharmacol Ther. 2022 Mar 11. doi: 10.1111/apt.16865.
    >> Share

  295. FALLOON K, Cohen B, Ananthakrishnan AN, Barnes EL, et al
    A United States expert consensus to standardise definitions, follow-up, and treatment targets for extra-intestinal manifestations in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2022 Mar 11. doi: 10.1111/apt.16853.
    >> Share

  296. SINGH AK, Jena A, Mahajan G, Mohindra R, et al
    Meta-analysis: Hepatitis B vaccination in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2022 Mar 8. doi: 10.1111/apt.16880.
    >> Share

  297. SUNG KY, Zhang B, Wang HE, Bai YM, et al
    Schizophrenia and risk of new-onset inflammatory bowel disease: a nationwide longitudinal study.
    Aliment Pharmacol Ther. 2022 Mar 8. doi: 10.1111/apt.16856.
    >> Share

  298. PANACCIONE R, Abreu MT, Lazariciu I, Mundayat R, et al
    Persistence of treatment in patients with ulcerative colitis who responded to tofacitinib therapy: Data from the open-label, long-term extension study, OCTAVE open.
    Aliment Pharmacol Ther. 2022 Mar 5. doi: 10.1111/apt.16848.
    >> Share

  299. JAYASOORIYA N, Blackwell J, Saxena S, Bottle A, et al
    Antidepressant medication use in Inflammatory Bowel Disease: a nationally representative population-based study.
    Aliment Pharmacol Ther. 2022 Mar 4. doi: 10.1111/apt.16820.
    >> Share

  300. SAVELKOUL EHJ, Hoentjen F
    Editorial: anti-TNF combination therapy for inflammatory bowel disease-one size does not fit all.
    Aliment Pharmacol Ther. 2022;55:750-751.
    >> Share

  301. HONAP S, Dart RJ, Samaan MA
    Editorial: protecting hypoxia-inducible factor-1alpha and gut integrity with GB004-a promising therapeutic approach for ulcerative colitis?
    Aliment Pharmacol Ther. 2022;55:733-734.
    >> Share

  302. DANESE S, Levesque BG, Feagan BG, Jucov A, et al
    Editorial: protecting hypoxia-inducible factor 1a and gut integrity with GB004-a promising therapeutic approach for ulcerative colitis? Authors' reply.
    Aliment Pharmacol Ther. 2022;55:735-736.
    >> Share

  303. KUMAR P, Vuyyuru SK, Kante B, Sahu P, et al
    Stringent screening strategy significantly reduces reactivation rates of tuberculosis in patients with inflammatory bowel disease on anti-TNF therapy in tuberculosis endemic region.
    Aliment Pharmacol Ther. 2022 Mar 1. doi: 10.1111/apt.16839.
    >> Share

  304. ZHAO M, Sall Jensen M, Knudsen T, Kelsen J, et al
    Trends in the use of biologicals and their treatment outcomes among patients with inflammatory bowel diseases - a Danish nationwide cohort study.
    Aliment Pharmacol Ther. 2022;55:541-557.
    >> Share

  305. COLMAN RJ, Xiong Y, Mizuno T, Hyams JS, et al
    Antibodies-to-infliximab accelerate clearance while dose intensification reverses immunogenicity and recaptures clinical response in paediatric Crohn's disease.
    Aliment Pharmacol Ther. 2022;55:593-603.
    >> Share

  306. COHEN NA, Pekow J
    Editorial: time to modify practice and use the modified Rutgeert's score.
    Aliment Pharmacol Ther. 2022;55:754-755.
    >> Share

  307. BANERJEE R, Raghunathan N
    Editorial: a paradigm shift in NUDT15 assessment-towards predictive and personalised medicine in Crohn's disease?
    Aliment Pharmacol Ther. 2022;55:740-741.
    >> Share

  308. KIM ES, Kang B
    Editorial: a paradigm shift in NUDT15 assessment-towards predictive and personalised medicine in Crohn's disease? Authors' reply.
    Aliment Pharmacol Ther. 2022;55:742-743.
    >> Share

    February 2022
  309. BALLESTER MP, Mesonero F, Florez-Diez P, Gomez C, et al
    Adherence to endoscopic surveillance for advanced lesions and colorectal cancer in inflammatory bowel disease: an AEG and GETECCU collaborative cohort study.
    Aliment Pharmacol Ther. 2022 Feb 27. doi: 10.1111/apt.16832.
    >> Share

  310. SAGAMI S, Kobayashi T, Aihara K, Umeda M, et al
    Early improvement in bowel wall thickness on transperineal ultrasonography predicts treatment success in active ulcerative colitis.
    Aliment Pharmacol Ther. 2022 Feb 25. doi: 10.1111/apt.16817.
    >> Share

  311. YE Z, Qian L, Hu W, Miao S, et al
    Clinical outcome of infantile-onset inflammatory bowel disease in 102 patients with interleukin-10 signalling deficiency.
    Aliment Pharmacol Ther. 2022 Feb 20. doi: 10.1111/apt.16837.
    >> Share

  312. GROSSBERG LB, Papamichael K, Cheifetz AS
    Review: emerging drug therapies in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2022 Feb 15. doi: 10.1111/apt.16785.
    >> Share

  313. WAN J, Wang X, Zhang Y, Chen M, et al
    Systematic review and meta-analysis: incidence and factors for progression to advanced neoplasia in inflammatory bowel disease patients with indefinite and low-grade dysplasia.
    Aliment Pharmacol Ther. 2022 Feb 15. doi: 10.1111/apt.16789.
    >> Share

  314. DEPUTY M, Sahnan K, Worley G, Patel K, et al
    The use of, and outcomes for, inflammatory bowel disease services during the Covid-19 pandemic: a nationwide observational study.
    Aliment Pharmacol Ther. 2022 Feb 7. doi: 10.1111/apt.16800.
    >> Share

  315. SCHREIBER S, Irving PM, Sharara AI, Martin-Arranz MD, et al
    Review: randomised controlled trials in inflammatory bowel disease-common challenges and potential solutions.
    Aliment Pharmacol Ther. 2022 Feb 7. doi: 10.1111/apt.16781.
    >> Share

  316. POLLOK RCG, Jayasooriya N
    Editorial: early and persistent biological treatment and its impact on long term surgical outcomes in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2022;55:370-371.
    >> Share

  317. TAXONERA C
    Editorial: real-world safety of tofacitinib in ulcerative colitis.
    Aliment Pharmacol Ther. 2022;55:368-369.
    >> Share

  318. MAHMOUD R, Schultheiss JPD, Fidder HH, Oldenburg B, et al
    Letter: loss of response to anti-TNFalpha agents depends on treatment duration in patients with inflammatory bowel disease-authors' reply.
    Aliment Pharmacol Ther. 2022;55:499-500.
    >> Share

  319. BEN-HORIN S, Ungar B
    Letter: loss of response to anti-TNFalpha agents in patients with inflammatory bowel disease depends on treatment duration.
    Aliment Pharmacol Ther. 2022;55:497-498.
    >> Share

  320. GOODSALL TM, Bryant RV
    Editorial: an accurate, reliable and responsive ultrasound activity score for Crohn's disease? Sounds good to US.
    Aliment Pharmacol Ther. 2022;55:360-361.
    >> Share

  321. ALLOCCA M, Danese S
    Editorial: an accurate, reliable and responsive ultrasound activity score for Crohn's disease? Sounds good to US. Authors' reply.
    Aliment Pharmacol Ther. 2022;55:362-363.
    >> Share

  322. ALLOCCA M, Craviotto V, Dell'Avalle C, Furfaro F, et al
    Bowel ultrasound score is accurate in assessing response to therapy in patients with Crohn's disease.
    Aliment Pharmacol Ther. 2022;55:446-454.
    >> Share

  323. SKEJO C, Vestergaard T, Julsgaard M
    Editorial: safety of ustekinumab in pregnancy-are we there yet?
    Aliment Pharmacol Ther. 2022;55:495-496.
    >> Share

  324. CARON B, Fumery M, Netter P, Peyrin-Biroulet L, et al
    Letter: treatment with subcutaneous CT-P13 in Crohn's disease patients with intravenous infliximab failure.
    Aliment Pharmacol Ther. 2022;55:508-509.
    >> Share

  325. PARROT L, Dong C, Carbonnel F, Meyer A, et al
    Systematic review with meta-analysis: the effectiveness of either ustekinumab or vedolizumab in patients with Crohn's disease refractory to anti-tumour necrosis factor.
    Aliment Pharmacol Ther. 2022;55:380-388.
    >> Share

    January 2022
  326. THOMSEN SB, Ungaro RC, Allin KH, Elmahdi R, et al
    Impact of thiopurine discontinuation at anti-tumour necrosis factor initiation in inflammatory bowel disease treatment: a nationwide Danish cohort study.
    Aliment Pharmacol Ther. 2022 Jan 25. doi: 10.1111/apt.16777.
    >> Share

  327. DANESE S, Levesque BG, Feagan BG, Jucov A, et al
    Randomised clinical trial: a phase 1b study of GB004, an oral HIF-1alpha stabiliser, for treatment of ulcerative colitis.
    Aliment Pharmacol Ther. 2022 Jan 10. doi: 10.1111/apt.16753.
    >> Share

  328. VEISMAN I, Ben-Horin S
    Editorial: tofacitinib post-marketing safety reports among ulcerative colitis patients.
    Aliment Pharmacol Ther. 2022;55:131-132.
    >> Share

  329. LAHARIE D, Riviere P
    Editorial: don't forget basic performance measures in the endoscopic assessment of ulcerative colitis.
    Aliment Pharmacol Ther. 2022;55:129-130.
    >> Share

  330. CARBONNEL F, Meyer A
    Editorial: subcutaneous CT-P13 in Crohn's disease and ulcerative colitis-small change, big consequences.
    Aliment Pharmacol Ther. 2022;55:251-252.
    >> Share

  331. GOREN I, Yanai H
    Editorial: risk of loss of response to anti-TNFalpha agents in patients with inflammatory bowel disease-the longer the less?
    Aliment Pharmacol Ther. 2022;55:244-245.
    >> Share

  332. HANZEL J, Bukkems LH, Gecse KB, D'Haens GR, et al
    Editorial: subcutaneous CT-P13 in Crohn's disease and ulcerative colitis-small change, big consequences. Authors' reply.
    Aliment Pharmacol Ther. 2022;55:253-254.
    >> Share

  333. VASUDEVAN A, van Langenberg DR
    Editorial: delving into the natural history of Crohn's disease and the impact of medical therapy.
    Aliment Pharmacol Ther. 2022;55:108-109.
    >> Share

  334. BURISCH J, Langholz E, Munkholm P
    Editorial: delving into the natural history of Crohn's disease and the impact of medical therapy-authors' reply.
    Aliment Pharmacol Ther. 2022;55:110-111.
    >> Share

  335. KHAN N, Patel D, Trivedi C, Pernes T, et al
    The impact of IBD medications on risk of pneumonia and pneumonia-related hospitalisation: a nationwide cohort study of 56 410 IBD patients.
    Aliment Pharmacol Ther. 2022;55:64-72.
    >> Share

  336. BURISCH J, Lophaven S, Langholz E, Munkholm P, et al
    The clinical course of Crohn's disease in a Danish population-based inception cohort with more than 50 years of follow-up, 1962-2017.
    Aliment Pharmacol Ther. 2022;55:73-82.
    >> Share

  337. REZAZADEH ARDABILI A, Mujagic Z, Jonkers DMAE, Pierik MJ, et al
    Letter: screening for infectious side effects in patients with IBD-the importance and potential of real-world remote monitoring.
    Aliment Pharmacol Ther. 2022;55:260-261.
    >> Share

  338. SCHULTHEISS JPD, Mahmoud R, Fidder HH, Oldenburg B, et al
    Editorial: risk of loss of response to anti TNFalpha in patients with inflammatory bowel diseases - the longer the less? Authors' reply.
    Aliment Pharmacol Ther. 2022;55:246.
    >> Share

  339. KHAN N, Yang YX
    Letter: screening for infectious side effects in patients with IBD-the importance and potential of real-world remote monitoring. Authors' reply.
    Aliment Pharmacol Ther. 2022;55:262.
    >> Share

  340. MA C, MacDonald JK, Nguyen TM, Chang J, et al
    Systematic review: disease activity indices for immune checkpoint inhibitor-associated enterocolitis.
    Aliment Pharmacol Ther. 2022;55:178-190.
    >> Share

    December 2021
  341. WANG J, Goren I, Yang B, Lin S, et al
    The sphingosine 1 phosphate/sphingosine 1 phosphate receptor axis: a unique therapeutic target in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2021 Dec 21. doi: 10.1111/apt.16741.
    >> Share

  342. FLANAGAN E, Prentice R, Wright EK, Gibson PR, et al
    Ustekinumab levels in pregnant women with inflammatory bowel disease and infants exposed in utero.
    Aliment Pharmacol Ther. 2021 Dec 14. doi: 10.1111/apt.16739.
    >> Share

  343. FORSS A, Clements M, Bergman D, Roelstraete B, et al
    A nationwide cohort study of the incidence of inflammatory bowel disease in Sweden from 1990 to 2014.
    Aliment Pharmacol Ther. 2021 Dec 14. doi: 10.1111/apt.16735.
    >> Share

  344. HADI Y, Dulai PS, Kupec J, Mohy-Ud-Din N, et al
    Incidence, outcomes, and impact of COVID-19 on inflammatory bowel disease: Propensity matched research network analysis.
    Aliment Pharmacol Ther. 2021 Dec 14. doi: 10.1111/apt.16730.
    >> Share

  345. CASEY K, Lopes EW, Niccum B, Burke K, et al
    Alcohol consumption and risk of inflammatory bowel disease among three prospective US cohorts.
    Aliment Pharmacol Ther. 2021 Dec 8. doi: 10.1111/apt.16731.
    >> Share

  346. MESERVE J, Singh S
    Editorial: risk of pneumonia in IBD-reading between the lines!
    Aliment Pharmacol Ther. 2021;54.
    >> Share

  347. HAMDEH S, Micic D, Hanauer S
    Review article: drug-induced small bowel injury.
    Aliment Pharmacol Ther. 2021;54.
    >> Share

  348. SANDBORN WJ, Lawendy N, Danese S, Su C, et al
    Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open-label, long-term extension study with up to 7.0 years of treatment.
    Aliment Pharmacol Ther. 2021 Dec 1. doi: 10.1111/apt.16712.
    >> Share

    November 2021
  349. ZHAO M, Feng R, Ben-Horin S, Zhuang X, et al
    Systematic review with meta-analysis: environmental and dietary differences of inflammatory bowel disease in Eastern and Western populations.
    Aliment Pharmacol Ther. 2021 Nov 24. doi: 10.1111/apt.16703.
    >> Share

  350. RADHAKRISHNAN ST, Alexander JL, Mullish BH, Gallagher KI, et al
    Systematic review: the association between the gut microbiota and medical therapies in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2021 Nov 9. doi: 10.1111/apt.16656.
    >> Share

  351. CHAO K, Huang Y, Zhu X, Tang J, et al
    Randomised clinical trial: dose optimising strategy by NUDT15 genotyping reduces leucopenia during thiopurine treatment of Crohn's disease.
    Aliment Pharmacol Ther. 2021;54:1124-1133.
    >> Share

    October 2021
  352. BURISCH J, Lophaven S, Munkholm P, Langholz E, et al
    Surgery, cancer and mortality among patients with ulcerative colitis diagnosed 1962-1987 and followed until 2017 in a Danish population-based inception cohort.
    Aliment Pharmacol Ther. 2021 Oct 29. doi: 10.1111/apt.16677.
    >> Share

  353. BEZZIO C, Armuzzi A, Furfaro F, Ardizzone S, et al
    Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV-2 infection: an IG-IBD study.
    Aliment Pharmacol Ther. 2021 Oct 25. doi: 10.1111/apt.16663.
    >> Share

  354. PASVOL TJ, Bloom S, Segal AW, Rait G, et al
    Use of contraceptives and risk of inflammatory bowel disease: A nested case-control study.
    Aliment Pharmacol Ther. 2021 Oct 18. doi: 10.1111/apt.16647.
    >> Share

  355. RUBIN DT, Modesto I, Vermeire S, Danese S, et al
    Worldwide post-marketing safety surveillance experience with tofacitinib in ulcerative colitis.
    Aliment Pharmacol Ther. 2021 Oct 9. doi: 10.1111/apt.16619.
    >> Share

  356. FEAGAN BG, Khanna R, Sandborn WJ, Vermeire S, et al
    Agreement between local and central reading of endoscopic disease activity in ulcerative colitis: results from the tofacitinib OCTAVE trials.
    Aliment Pharmacol Ther. 2021 Oct 6. doi: 10.1111/apt.16626.
    >> Share

  357. TAKENAKA K, Kawamoto A, Ohtsuka K
    Editorial: higher concentrations of cytokine blockers are needed to obtain small bowel mucosal healing during maintenance therapy in Crohn's disease-authors' reply.
    Aliment Pharmacol Ther. 2021;54:1087.
    >> Share

  358. RAKOWSKY S, Cheifetz AS, Papamichael K
    Editorial: higher concentrations of cytokine blockers are needed to obtain small bowel mucosal healing during maintenance therapy in Crohn's disease.
    Aliment Pharmacol Ther. 2021;54:1085-1086.
    >> Share

  359. JOLVING LR, Anru PL, Nielsen J, Friedman S, et al
    The risk of chronic diseases and congenital malformations during childhood and adolescence after in utero exposure to thiopurines.
    Aliment Pharmacol Ther. 2021;54:1061-1069.
    >> Share

  360. SAINZ E, Zabana Y, Miguel I, Fernandez-Clotet A, et al
    Clinical features, therapeutic requirements and evolution of patients with Crohn's disease and upper gastrointestinal involvement (CROHNEX study).
    Aliment Pharmacol Ther. 2021;54:1041-1051.
    >> Share

  361. TAKENAKA K, Kawamoto A, Hibiya S, Suzuki K, et al
    Higher concentrations of cytokine blockers are needed to obtain small bowel mucosal healing during maintenance therapy in Crohn's disease.
    Aliment Pharmacol Ther. 2021;54:1052-1060.
    >> Share

    September 2021
  362. MULES TC, Swaminathan A, Hirschfeld E, Borichevsky G, et al
    The impact of disease activity on psychological symptoms and quality of life in patients with inflammatory bowel disease-results from the Stress, Anxiety and Depression with Disease Activity (SADD) Study.
    Aliment Pharmacol Ther. 2021 Sep 29. doi: 10.1111/apt.16616.
    >> Share

  363. SCHULTHEISS JPD, Mahmoud R, Louwers JM, van der Kaaij MT, et al
    Loss of response to anti-TNFalpha agents depends on treatment duration in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2021 Sep 24. doi: 10.1111/apt.16605.
    >> Share

  364. HANZEL J, Bukkems LH, Gecse KB, D'Haens GR, et al
    Population pharmacokinetics of subcutaneous infliximab CT-P13 in Crohn's disease and ulcerative colitis.
    Aliment Pharmacol Ther. 2021 Sep 24. doi: 10.1111/apt.16609.
    >> Share

  365. DOHERTY J, Fennessy S, Stack R, O' Morain N, et al
    Review Article: Vaccination for patients with inflammatory bowel disease during the COVID-19 pandemic.
    Aliment Pharmacol Ther. 2021 Sep 2. doi: 10.1111/apt.16590.
    >> Share

  366. SAITTA D, Garg M
    Letter: missed opportunities for the diagnosis of colorectal cancer in patients with inflammatory bowel disease-still significant room for improvement.
    Aliment Pharmacol Ther. 2021;54:734-735.
    >> Share

  367. BLESL A, Hogenauer C, Borenich A, Berghold A, et al
    Editorial: does anti-TNF 'treatment persistence' always equate to 'effective treatment'? Only objective disease assessments can answer the question. Authors' reply.
    Aliment Pharmacol Ther. 2021;54:720-721.
    >> Share

  368. BLESL A, Binder L, Hogenauer C, Wenzl H, et al
    Limited long-term treatment persistence of first anti-TNF therapy in 538 patients with inflammatory bowel diseases: a 20-year real-world study.
    Aliment Pharmacol Ther. 2021;54:667-677.
    >> Share

  369. VISURI I, Eriksson C, Olen O, Cao Y, et al
    Editorial: infliximab or adalimumab as first- or second-line anti-TNF-conflicting evidence-authors' reply.
    Aliment Pharmacol Ther. 2021;54:848-849.
    >> Share

  370. VEYRARD P, Nancey S, Roblin X
    Editorial: 5-ASA in IBD patients on biologics-'stop or continue'?
    Aliment Pharmacol Ther. 2021;54:843-844.
    >> Share

  371. BERNSTEIN CN, Tennakoon A, Singh H, Targownik L, et al
    Editorial: 5-ASA in IBD patients on biologics-'stop or continue'? Authors' reply.
    Aliment Pharmacol Ther. 2021;54:845.
    >> Share

  372. HAYDEK JP, Scott FI
    Editorial: infliximab or adalimumab as first- or second-line anti-TNF-conflicting evidence.
    Aliment Pharmacol Ther. 2021;54:846-847.
    >> Share

  373. PIERRE N, Salee C, Vieujean S, Bequet E, et al
    Review article: distinctions between ileal and colonic Crohn's disease: from physiology to pathology.
    Aliment Pharmacol Ther. 2021;54:779-791.
    >> Share

  374. BERNSTEIN CN, Tenakoon A, Singh H, Targownik LE, et al
    Continued 5ASA use after initiation of anti-TNF or immunomodulator confers no benefit in IBD: a population-based study.
    Aliment Pharmacol Ther. 2021;54:814-832.
    >> Share

    August 2021
  375. SLEUTJES JAM, Roeters van Lennep JE, Boersma E, Menchen LA, et al
    Systematic review with meta-analysis: effect of inflammatory bowel disease therapy on lipid levels.
    Aliment Pharmacol Ther. 2021 Aug 28. doi: 10.1111/apt.16580.
    >> Share

  376. HONAP S, Pavlidis P, Irving PM
    Editorial: is tofacitinib another rescue option for acute severe ulcerative colitis?
    Aliment Pharmacol Ther. 2021;54:341-342.
    >> Share

  377. BIEMANS VBC, Straatmijer T, Hoentjen F, Pierik MJ, et al
    Letter: tofacitinib in treatment-refractory ulcerative colitis-a single centre real-world experience in Australia. Authors' reply.
    Aliment Pharmacol Ther. 2021;54:534-535.
    >> Share

  378. LO SW, Connell W, Kamm MA, Lust M, et al
    Letter: tofacitinib in biologic-experienced ulcerative colitis-a single-centre real-world experience in Australia.
    Aliment Pharmacol Ther. 2021;54:532-533.
    >> Share

  379. ROBLIN X, Nancey S, Paul S
    Letter: predicting treatment discontinuation in inflammatory bowel disease-anti-TNF trough levels and anti-drug antibodies. Authors' reply.
    Aliment Pharmacol Ther. 2021;54:538-539.
    >> Share

  380. FRIEDMAN AB, Gibson PR
    Editorial: assessment of inflammatory bowel disease: a picture is worth a thousand words. Authors' reply.
    Aliment Pharmacol Ther. 2021;54:510.
    >> Share

  381. HORJUS-TALABUR HORJE CS, van Bodegraven AA
    Editorial: assessment of inflammatory bowel disease-a picture is worth a thousand words.
    Aliment Pharmacol Ther. 2021;54:508-509.
    >> Share

  382. TSOI AH, Murugasu A, Garg M
    Letter: assessment of histological disease activity in Crohn's disease clinical trials-a step in the right direction, but further optimisation needed.
    Aliment Pharmacol Ther. 2021;54:541-542.
    >> Share

  383. DEMARZO MG, Bodini G, Giuliana E, Zentilin P, et al
    Letter: predictive factors for treatment discontinuation in IBD-anti-TNF trough levels and anti-drug antibodies.
    Aliment Pharmacol Ther. 2021;54:536-537.
    >> Share

  384. MATTOO VY, Basnayake C, Connell WR, Ding N, et al
    Systematic review: efficacy of escalated maintenance anti-tumour necrosis factor therapy in Crohn's disease.
    Aliment Pharmacol Ther. 2021;54:249-266.
    >> Share

    July 2021
  385. LAMBERT K, Pappas D, Miglioretto C, Javadpour A, et al
    Systematic review with meta-analysis: dietary intake in adults with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2021 Jul 29. doi: 10.1111/apt.16549.
    >> Share

  386. FUMERY M, Filippi J, Abitbol V, Biron A, et al
    Effectiveness and safety of ustekinumab maintenance therapy in 103 patients with ulcerative colitis: a GETAID cohort study.
    Aliment Pharmacol Ther. 2021 Jul 23. doi: 10.1111/apt.16544.
    >> Share

  387. VISURI I, Eriksson C, Olen O, Cao Y, et al
    Predictors of drug survival: A cohort study comparing anti-tumour necrosis factor agents using the Swedish inflammatory bowel disease quality register.
    Aliment Pharmacol Ther. 2021 Jul 19. doi: 10.1111/apt.16525.
    >> Share

  388. MCGING JJ, Radford SJ, Francis ST, Serres S, et al
    Review article: The aetiology of fatigue in inflammatory bowel disease and potential therapeutic management strategies.
    Aliment Pharmacol Ther. 2021 Jul 6. doi: 10.1111/apt.16465.
    >> Share

  389. LUBER RP, O'Neill R, Singh S, Sharma E, et al
    An observational study of switching infliximab biosimilar: no adverse impact on inflammatory bowel disease control or drug levels with first or second switch.
    Aliment Pharmacol Ther. 2021 Jul 5. doi: 10.1111/apt.16497.
    >> Share

  390. ROTONDO-TRIVETTE S, Wang B, Gayer C, Parsana R, et al
    Decreased secondary faecal bile acids in children with ulcerative colitis and Clostridioides difficile infection.
    Aliment Pharmacol Ther. 2021 Jul 4. doi: 10.1111/apt.16496.
    >> Share

  391. OSENI E, Sultan K
    Letter: opioid use, early biologic discontinuation for inflammatory bowel disease and a cautionary note for the age of legalised cannabis.
    Aliment Pharmacol Ther. 2021;54:92-93.
    >> Share

  392. JORDI SBU, Misselwitz B, Begre S
    Editorial: type D personality and its relationship with depression and disease activity in inflammatory bowel disease-authors' reply.
    Aliment Pharmacol Ther. 2021;54:82-83.
    >> Share

  393. KNOWLES SR, Mikocka-Walus A
    Editorial: type D personality and its relationship with depression and disease activity in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2021;54:80-81.
    >> Share

  394. FAN D, Gearry RB
    Editorial: IBD medications during the COVID-19 pandemic-are they safe to use?
    Aliment Pharmacol Ther. 2021;54:208-209.
    >> Share

  395. TASSONE D, Singh S, Sheng Ding N
    Editorial: impact of body mass index on clinical outcomes in patients with ulcerative colitis treated with tofacitinib.
    Aliment Pharmacol Ther. 2021;54:206-207.
    >> Share

  396. MEYER A, Semenzato L, Zureik M, Weill A, et al
    Risk of severe COVID-19 in patients treated with IBD medications: a French nationwide study.
    Aliment Pharmacol Ther. 2021;54:160-166.
    >> Share

  397. CASANOVA MJ, Chaparro M, Gisbert JP
    Editorial: withdrawal of anti-TNFalpha-are we ready for biological therapy cycling? Authors' reply.
    Aliment Pharmacol Ther. 2021;54:86-87.
    >> Share

  398. PUGLIESE D, Armuzzi A
    Editorial: withdrawal of anti TNF-alpha - are we ready for biological therapy cycling?
    Aliment Pharmacol Ther. 2021;54:84-85.
    >> Share

  399. WEISSHOF R, Chowers Y, Kurnik D
    Editorial: safety of thiopurines in pregnancy-considering the mother, foetus and newborn.
    Aliment Pharmacol Ther. 2021;54:88-89.
    >> Share

    June 2021
  400. FARRAYE FA, Qazi T, Kotze PG, Moore GT, et al
    The impact of body mass index on efficacy and safety in the tofacitinib OCTAVE ulcerative colitis clinical programme.
    Aliment Pharmacol Ther. 2021 Jun 24. doi: 10.1111/apt.16439.
    >> Share

  401. MEYER A, Drouin J, Weill A, Carbonnel F, et al
    Comparative study of pregnancy outcomes in women with inflammatory bowel disease treated with thiopurines and/or anti-TNF: a French nationwide study 2010-2018.
    Aliment Pharmacol Ther. 2021 Jun 23. doi: 10.1111/apt.16448.
    >> Share

  402. FRIEDMAN AB, Asthana A, Knowles SR, Robbins A, et al
    Effect of point-of-care gastrointestinal ultrasound on decision-making and management in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2021 Jun 22. doi: 10.1111/apt.16452.
    >> Share

  403. BERNSTEIN CN, Nugent Z, Shaffer S, Singh H, et al
    Comorbidity before and after a diagnosis of inflammatory bowel disease.
    Aliment Pharmacol Ther. 2021 Jun 22. doi: 10.1111/apt.16444.
    >> Share

  404. UZZAN M, Bresteau C, Laharie D, Stefanescu C, et al
    Tofacitinib as salvage therapy for 55 patients hospitalised with refractory severe ulcerative colitis: A GETAID cohort.
    Aliment Pharmacol Ther. 2021 Jun 20. doi: 10.1111/apt.16463.
    >> Share

  405. KO Y, Paramsothy S, Yau Y, Leong RW, et al
    Superior treatment persistence with ustekinumab in Crohn's disease and vedolizumab in ulcerative colitis compared with anti-TNF biological agents: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) study.
    Aliment Pharmacol Ther. 2021 Jun 20. doi: 10.1111/apt.16436.
    >> Share

  406. VAN LINSCHOTEN RCA, Visser E, Niehot CD, van der Woude CJ, et al
    Systematic review: societal cost of illness of inflammatory bowel disease is increasing due to biologics and varies between continents.
    Aliment Pharmacol Ther. 2021 Jun 11. doi: 10.1111/apt.16445.
    >> Share

  407. FAIRBRASS KM, Gracie DJ, Ford AC
    Longitudinal follow-up study: effect of psychological co-morbidity on the prognosis of inflammatory bowel disease.
    Aliment Pharmacol Ther. 2021 Jun 11. doi: 10.1111/apt.16454.
    >> Share

  408. LAMB CA, Sebastian S, Kent AJ, Segal JP, et al
    Letter: risk of severe COVID-19 outcomes associated with inflammatory bowel disease medications-reassuring insights from the United Kingdom PREPARE-IBD multicentre cohort study.
    Aliment Pharmacol Ther. 2021;53:1236-1240.
    >> Share

  409. EL-MATARY W, Nugent Z, Witt J, Bernstein CN, et al
    Editorial: trends in paediatric inflammatory bowel disease attributable direct costs-authors' reply.
    Aliment Pharmacol Ther. 2021;53:1234-1235.
    >> Share

  410. VERNON-ROBERTS A, Day AS
    Editorial: trends in paediatric inflammatory bowel disease attributable direct costs.
    Aliment Pharmacol Ther. 2021;53:1232-1233.
    >> Share

  411. TANNOURY J, Amiot A
    Editorial: determining disability in inflammatory bowel disease-"See(k) and you shall find". Authors' reply.
    Aliment Pharmacol Ther. 2021;53:1323.
    >> Share

  412. TURBAYNE AKB, Ward MG
    Editorial: total anti-drug antibodies detected using drug-tolerant assays during induction with anti-TNF therapy are associated with treatment failure-out of sight but not out of mind.
    Aliment Pharmacol Ther. 2021;53:1317-1318.
    >> Share

  413. ROBLIN X, Nancey S, Paul S
    Editorial: total anti-drug antibodies detected using drug-tolerant assays during induction with anti-TNF therapy are associated with treatment failure-out of sight but not out of mind. Authors' reply.
    Aliment Pharmacol Ther. 2021;53:1319-1320.
    >> Share

  414. LIMDI JK
    Editorial: determining disability in IBD - 'See(k) and you shall find'.
    Aliment Pharmacol Ther. 2021;53:1321-1322.
    >> Share

  415. MANLAY L, Boschetti G, Pereira B, Flourie B, et al
    Comparison of short- and long-term effectiveness between ustekinumab and vedolizumab in patients with Crohn's disease refractory to anti-tumour necrosis factor therapy.
    Aliment Pharmacol Ther. 2021;53:1289-1299.
    >> Share

    May 2021
  416. JORDI SBU, Botte F, Lang BM, Greuter T, et al
    Type D personality is associated with depressive symptoms and clinical activity in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2021 May 11. doi: 10.1111/apt.16365.
    >> Share

  417. CASANOVA MJ, Chaparro M, Nantes O, Benitez JM, et al
    Clinical outcome after anti-tumour necrosis factor therapy discontinuation in 1000 patients with inflammatory bowel disease: the EVODIS long-term study.
    Aliment Pharmacol Ther. 2021 May 7. doi: 10.1111/apt.16361.
    >> Share

  418. SRINIVASAN A, Haifer C, Thin L
    Editorial: outcomes following a second switch-evaluating clinical outcomes and patient perspectives in IBD.
    Aliment Pharmacol Ther. 2021;53:1038-1039.
    >> Share

  419. WILSON A, Kim RB
    Letter: genetic variation in the HLA-DQA1*05 allele predicts tumour necrosis factor-alpha antagonist immunogenicity - does location matter?
    Aliment Pharmacol Ther. 2021;53:1055-1056.
    >> Share

  420. DEMARZO MG, Bodini G, Vanello M, Martini M, et al
    Letter: vedolizumab or a second anti-TNF-no difference in efficacy for primary biologic failures with IBD.
    Aliment Pharmacol Ther. 2021;53:1044-1045.
    >> Share

  421. RUNDQUIST S, Sachs MC, Eriksson C, Olen O, et al
    Letter: vedolizumab or a second anti-TNF-no difference in efficacy for primary biologic failures with IBD. Authors' reply.
    Aliment Pharmacol Ther. 2021;53:1046-1047.
    >> Share

  422. MESONERO F, Castro-Poceiro J, Benitez JM, Camps B, et al
    Effectiveness and safety of methotrexate monotherapy in patients with Crohn's disease refractory to anti-TNF-alpha: results from the ENEIDA registry.
    Aliment Pharmacol Ther. 2021;53:1021-1029.
    >> Share

  423. SEDANO R, Ma C, Jairath V
    Editorial: standardising inclusion and outcome criteria for pouchitis-a fragile consensus perhaps but a first step in the right direction. Authors' reply.
    Aliment Pharmacol Ther. 2021;53:1149-1150.
    >> Share

  424. LAUBE R, Selinger CP
    Editorial: standardising inclusion and outcome criteria for pouchitis-a fragile consensus perhaps but a first step in the right direction.
    Aliment Pharmacol Ther. 2021;53:1147-1148.
    >> Share

  425. TANNOURY J, Nachury M, Martins C, Serrero M, et al
    Determinants of IBD-related disability: a cross-sectional survey from the GETAID.
    Aliment Pharmacol Ther. 2021;53:1098-1107.
    >> Share

  426. TJANDRA D, Garg M, Behrenbruch C, McCormick J, et al
    Review article: investigation and management of internal fistulae in Crohn's disease.
    Aliment Pharmacol Ther. 2021;53:1064-1079.
    >> Share

    April 2021
  427. DHALIWAL J, McKay HE, Deslandres C, Debruyn J, et al
    One-year outcomes with ustekinumab therapy in infliximab-refractory paediatric ulcerative colitis: a multicentre prospective study.
    Aliment Pharmacol Ther. 2021 Apr 28. doi: 10.1111/apt.16388.
    >> Share

  428. TOURNIER Q, Paul S, Williet N, Berger AE, et al
    Early detection of anti-drug antibodies during initiation of anti-tumour necrosis factor therapy predicts treatment discontinuation in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2021 Apr 19. doi: 10.1111/apt.16333.
    >> Share

  429. EL-MATARY W, Nugent Z, Witt J, Bernstein CN, et al
    Trends in paediatric inflammatory bowel disease-attributable direct costs: a population-based analysis.
    Aliment Pharmacol Ther. 2021 Apr 9. doi: 10.1111/apt.16358.
    >> Share

  430. VAN DER HAVE M, Maljaars J
    Editorial: opioids in inflammatory bowel disease-primum non nocere.
    Aliment Pharmacol Ther. 2021;53:844-845.
    >> Share

  431. RHUDY C, Perry CL, Barrett TA
    Editorial: opioids in inflammatory bowel disease-primum non nocere. Authors' reply.
    Aliment Pharmacol Ther. 2021;53:846.
    >> Share

  432. JANGI S, Yoon H, Dulai P, Valasek M, et al
    Letter: the combination of histologic remission and Mayo endoscopic score 1 as a suitable therapeutic target in ulcerative colitis-authors' reply.
    Aliment Pharmacol Ther. 2021;53:957-958.
    >> Share

  433. MAEDA Y, Kudo SE, Takishima K, Misawa M, et al
    Letter: the combination of histologic remission and Mayo endoscopic score 1 as a suitable therapeutic target in ulcerative colitis.
    Aliment Pharmacol Ther. 2021;53:955-956.
    >> Share

  434. PRENTICE RE, Hollingsworth L, Middleton C, Wilson J, et al
    Letter: colorectal cancer surveillance in inflammatory bowel disease-a call for systematic reform.
    Aliment Pharmacol Ther. 2021;53:953-954.
    >> Share

  435. LUBELL JM
    Letter: future studies of high-dose thiamine should consider whether its effects on fatigue are related to the inhibition of carbonic anhydrase isoenzymes.
    Aliment Pharmacol Ther. 2021;53:851-852.
    >> Share

  436. BAGER P, Hvas C, Rud C, Dahlerup J, et al
    Letter: future studies of high-dose thiamine should consider whether its effects on fatigue are related to the inhibition of carbonic anhydrase isoenzymes. Authors' reply.
    Aliment Pharmacol Ther. 2021;53:853-854.
    >> Share

  437. LIM G, Kassam Z, Seow CH
    Letter: is the radiation therapy causing an IBD flare, or the IBD predisposing to radiation toxicity?
    Aliment Pharmacol Ther. 2021;53:855-856.
    >> Share

  438. TURSI A, Mocci G, Picchio M, Elisei W, et al
    Letter: ustekinumab for the treatment of post-surgical and refractory Crohn's disease.
    Aliment Pharmacol Ther. 2021;53:859-860.
    >> Share

  439. LAHARIE D, Riviere P
    Letter: is the radiation therapy causing an IBD flare, or the IBD predisposing to radiation toxicity? Authors' reply.
    Aliment Pharmacol Ther. 2021;53:857-858.
    >> Share

  440. ALMRADI A, Ma C, D'Haens GR, Sandborn WJ, et al
    An expert consensus to standardise the assessment of histological disease activity in Crohn's disease clinical trials.
    Aliment Pharmacol Ther. 2021;53:784-793.
    >> Share

  441. ABUSHAMMA S, Deepak P
    Editorial: use of intestinal ultrasound in the scoring of Crohn's disease activity in clinical trials-is it ready for prime time yet?
    Aliment Pharmacol Ther. 2021;53:946-947.
    >> Share

  442. JAIRATH V, Almradi A, Pai RK, Ma C, et al
    Editorial: an expert consensus to standardise the assessment of histological disease activity in Crohn's disease clinical trials-a missing link. Authors' reply.
    Aliment Pharmacol Ther. 2021;53:952.
    >> Share

  443. TANDON P, Narula N
    Editorial: methotrexate in patients with Crohn's disease refractory to anti-TNF therapy-moving backwards yet forward?
    Aliment Pharmacol Ther. 2021;53:950-951.
    >> Share

  444. GOODSALL TM, Jairath V, Bryant RV, Ma C, et al
    Editorial: use of intestinal ultrasound in the scoring of Crohn's disease activity in clinical trials - is it ready for prime time yet? Authors' reply.
    Aliment Pharmacol Ther. 2021;53:948-949.
    >> Share

  445. GOODSALL TM, Jairath V, Feagan BG, Parker CE, et al
    Standardisation of intestinal ultrasound scoring in clinical trials for luminal Crohn's disease.
    Aliment Pharmacol Ther. 2021;53:873-886.
    >> Share

    March 2021
  446. WORLEY G, Faiz O
    Editorial: time trends in colectomy rates for ulcerative colitis in England-mixed methods brings mixed messages? Authors' reply.
    Aliment Pharmacol Ther. 2021;53:661-662.
    >> Share

  447. BODGER K
    Editorial: time trends in colectomy rates for ulcerative colitis in England-mixed methods brings mixed messages?
    Aliment Pharmacol Ther. 2021;53:660.
    >> Share

  448. LAHARIE D
    Editorial: is enteral nutrition back in acute severe ulcerative colitis?
    Aliment Pharmacol Ther. 2021;53:745-746.
    >> Share

  449. AL-ANI AH, Prentice RE, Rentsch C, Christensen B, et al
    Letter: SARS-CoV-2 infection in two inflammatory bowel disease patients treated with dual targeted therapy-Authors' reply.
    Aliment Pharmacol Ther. 2021;53:766-767.
    >> Share

  450. SAHU P, Kedia S, Kumar Vuyyuru S, Travis S, et al
    Editorial: is enteral nutrition back in acute severe ulcerative colitis? Authors' reply.
    Aliment Pharmacol Ther. 2021;53:747-748.
    >> Share

  451. O'MORAIN N, Coe C, Mallon P, Twomey P, et al
    Letter: how frequently does COVID-19 mimic an IBD flare when community transmission of SARS-CoV-2 is active?
    Aliment Pharmacol Ther. 2021;53:674-675.
    >> Share

  452. PRIVITERA G, Pugliese D, Scaldaferri F, Armuzzi A, et al
    Letter: SARS-CoV-2 infection in two IBD patients treated with dual targeted therapy.
    Aliment Pharmacol Ther. 2021;53:764-765.
    >> Share

  453. TRYSTRAM N, Abitbol V, Tannoury J, Lecomte M, et al
    Outcomes after double switching from originator Infliximab to biosimilar CT-P13 and biosimilar SB2 in patients with inflammatory bowel disease: a 12-month prospective cohort study.
    Aliment Pharmacol Ther. 2021 Mar 1. doi: 10.1111/apt.16312.
    >> Share

  454. KANESHIRO M, Takenaka K, Suzuki K, Fujii T, et al
    Pancolonic endoscopic and histologic evaluation for relapse prediction in patients with ulcerative colitis in clinical remission.
    Aliment Pharmacol Ther. 2021 Mar 1. doi: 10.1111/apt.16310.
    >> Share

  455. MANTZARIS GJ, Bamias G
    Editorial: an expert consensus to standardise the assessment of histologic disease activity in Crohn's disease clinical trials-a missing link.
    Aliment Pharmacol Ther. 2021;53:749-750.
    >> Share

  456. ROBLIN X, Paul S, Nancey S
    Editorial: anti-TNF agents against vedolizumab as a second-line treatment? Not surprising tie game.
    Aliment Pharmacol Ther. 2021;53:640-641.
    >> Share

  457. RUNDQUIST S, Sachs MC, Eriksson C, Olen O, et al
    Editorial: anti-TNF agents against vedolizumab as a second-line treatment? Not surprising tie game-authors' reply.
    Aliment Pharmacol Ther. 2021;53:642-643.
    >> Share

  458. MCCURDY J, Boet S, Rosenfeld G
    Editorial: is hyperbaric oxygen a therapeutic opportunity for refractory perianal Crohn's disease?
    Aliment Pharmacol Ther. 2021;53:667-668.
    >> Share

  459. LAFEUILLE P, Hordonneau C, Vignette J, Blayac L, et al
    Transmural healing and MRI healing are associated with lower risk of bowel damage progression than endoscopic mucosal healing in Crohn's disease.
    Aliment Pharmacol Ther. 2021;53:577-586.
    >> Share

  460. LANSDORP CA, Gecse KB, Buskens CJ, Lowenberg M, et al
    Hyperbaric oxygen therapy for the treatment of perianal fistulas in 20 patients with Crohn's disease.
    Aliment Pharmacol Ther. 2021;53:587-597.
    >> Share

    February 2021
  461. FLANAGAN E, Wright EK, Hardikar W, Sparrow MP, et al
    Maternal thiopurine metabolism during pregnancy in inflammatory bowel disease and clearance of thiopurine metabolites and outcomes in exposed neonates.
    Aliment Pharmacol Ther. 2021 Feb 19. doi: 10.1111/apt.16294.
    >> Share

  462. JAHRAUS CD
    Editorial: "Please Sir, I want some more" data to guide delivery of abdominopelvic radiotherapy in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2021;53:454-455.
    >> Share

  463. AXELRAD JE
    Editorial: immune-mediated diseases-are we closer to disease-defining molecular signatures?
    Aliment Pharmacol Ther. 2021;53:563-564.
    >> Share

  464. DANESE S, Subramaniam K, Van Zyl J, Adsul S, et al
    Editorial: vedolizumab in inflammatory bowel diseases-less is more? Authors' reply.
    Aliment Pharmacol Ther. 2021;53:445-446.
    >> Share

  465. WILS P, Pariente B
    Editorial: keep calm and carry on-managing non-TNF antagonist biologics in pregnancy-authors' reply.
    Aliment Pharmacol Ther. 2021;53:452-453.
    >> Share

  466. SEOW CH, Ma C
    Keep calm and carry on-managing non-TNF antagonist biologics in pregnancy.
    Aliment Pharmacol Ther. 2021;53:450-451.
    >> Share

  467. TOWNSEND T, Subramanian S
    Editorial: vedolizumab in inflammatory bowel diseases-less is more?
    Aliment Pharmacol Ther. 2021;53:443-444.
    >> Share

  468. MESERVE J, Facciorusso A, Holmer AK, Annese V, et al
    Systematic review with meta-analysis: safety and tolerability of immune checkpoint inhibitors in patients with pre-existing inflammatory bowel diseases.
    Aliment Pharmacol Ther. 2021;53:374-382.
    >> Share

    January 2021
  469. RHUDY C, Perry CL, Singleton M, Talbert J, et al
    Chronic opioid use is associated with early biologic discontinuation in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2021 Jan 26. doi: 10.1111/apt.16269.
    >> Share

  470. SAHU P, Kedia S, Vuyyuru SK, Bajaj A, et al
    Randomised clinical trial: exclusive enteral nutrition versus standard of care for acute severe ulcerative colitis.
    Aliment Pharmacol Ther. 2021 Jan 13. doi: 10.1111/apt.16249.
    >> Share

  471. CHEE D, Kennedy NA, Goodhand JR, Ahmad T, et al
    Editorial: missed opportunities to detect colorectal cancer in inflammatory bowel disease-getting to the root. Authors' reply.
    Aliment Pharmacol Ther. 2021;53:337-338.
    >> Share

  472. MAHMOUD R, Itzkowitz SH
    Editorial: missed opportunities to detect colorectal cancer in inflammatory bowel disease-getting to the root.
    Aliment Pharmacol Ther. 2021;53:335-336.
    >> Share

  473. LORD A, Radford-Smith G
    Letter: hidden costs in healthcare use for incident and prevalent Crohn's disease and ulcerative colitis.
    Aliment Pharmacol Ther. 2021;53:368-369.
    >> Share

  474. RIMOLA J, Panes J, Ordas I
    Letter: accuracy of magnetic resonance index of activity score to predict response to biologics in Crohn's disease-authors' reply.
    Aliment Pharmacol Ther. 2021;53:207-208.
    >> Share

  475. DEBNATH P, Rathi P
    Letter: accuracy of magnetic resonance index of activity score to predict response to biologics in Crohn's disease.
    Aliment Pharmacol Ther. 2021;53:205-206.
    >> Share

  476. MURRAY CD
    Editorial: fatigue-difficult to assess and difficult to treat.
    Aliment Pharmacol Ther. 2021;53:339.
    >> Share

  477. LEBLANC JF, Hart AL
    Editorial: a pipe dream fulfilled? A therapeutic option for fatigue in IBD.
    Aliment Pharmacol Ther. 2021;53:342-343.
    >> Share

  478. TOWNSEND T, Subramanian S
    Letter: propensity score-handle with care. Authors' reply.
    Aliment Pharmacol Ther. 2021;53:362-363.
    >> Share

  479. MACALUSO FS, Orlando A
    Letter: propensity score-handle with care.
    Aliment Pharmacol Ther. 2021;53:360-361.
    >> Share

  480. CARBERY I, Selinger CP
    Editorial: can serum triiodothyronine-to-thyroxine (T3/T4) ratio predict safety and efficacy of biologic treatment in IBD?
    Aliment Pharmacol Ther. 2021;53:346-347.
    >> Share

  481. BAGER P, Hvas CL, Rud CL, Dahlerup JF, et al
    Editorial: a pipe dream fulfilled? A therapeutic option for fatigue in IBD. Authors' reply.
    Aliment Pharmacol Ther. 2021;53:344-345.
    >> Share

  482. SCHREINER P, von Kanel R, Misselwitz B
    Editorial: fatigue-difficult to assess and difficult to treat. Authors' reply.
    Aliment Pharmacol Ther. 2021;53:340-341.
    >> Share

  483. BERTANI L, Pugliese D, Trico D, Costa F, et al
    Editorial: can serum triiodothyronine-to-thyroxine (T3/T4) ratio predict safety and efficacy of biologic treatment in IBD? Authors' reply.
    Aliment Pharmacol Ther. 2021;53:348-349.
    >> Share

  484. NICE R, Chanchlani N, Green H, Bewshea C, et al
    Validating the positivity thresholds of drug-tolerant anti-infliximab and anti-adalimumab antibody assays.
    Aliment Pharmacol Ther. 2021;53:128-137.
    >> Share

  485. DANESE S, Subramaniam K, Van Zyl J, Adsul S, et al
    Vedolizumab treatment persistence and safety in a 2-year data analysis of an extended access programme.
    Aliment Pharmacol Ther. 2021;53:265-272.
    >> Share

  486. BERTANI L, Trico D, Pugliese D, Privitera G, et al
    Serum triiodothyronine-to-thyroxine (T3/T4) ratio predicts therapeutic outcome to biological therapies in elderly IBD patients.
    Aliment Pharmacol Ther. 2021;53:273-280.
    >> Share

  487. FRAZZONI L, La Marca M, Radaelli F, Spada C, et al
    Systematic review with meta-analysis: the appropriateness of colonoscopy increases the probability of relevant findings and cancer while reducing unnecessary exams.
    Aliment Pharmacol Ther. 2021;53:22-32.
    >> Share

  488. PAI RK, Pai RK, Brown I, Choi WT, et al
    The significance of histological activity measurements in immune checkpoint inhibitor colitis.
    Aliment Pharmacol Ther. 2021;53:150-159.
    >> Share

  489. UNGARO RC, Hu L, Ji J, Nayar S, et al
    Machine learning identifies novel blood protein predictors of penetrating and stricturing complications in newly diagnosed paediatric Crohn's disease.
    Aliment Pharmacol Ther. 2021;53:281-290.
    >> Share

  490. KING D, Coupland B, Dosanjh A, Cole A, et al
    The risk of later surgery at the anastomotic site following right hemicolectomy for Crohn's disease in a national cohort of 12 230 patients.
    Aliment Pharmacol Ther. 2021;53:114-127.
    >> Share

    December 2020
  491. RUNDQUIST S, Sachs MC, Eriksson C, Olen O, et al
    Drug survival of anti-TNF agents compared with vedolizumab as a second-line biological treatment in inflammatory bowel disease: results from nationwide Swedish registers.
    Aliment Pharmacol Ther. 2020 Dec 19. doi: 10.1111/apt.16193.
    >> Share

  492. YE L, Chapman TP, Wen Z, Lin L, et al
    Targeted versus universal tuberculosis chemoprophylaxis in 1968 patients with inflammatory bowel disease receiving anti-TNF therapy in a tuberculosis endemic region.
    Aliment Pharmacol Ther. 2020 Dec 12. doi: 10.1111/apt.16130.
    >> Share

  493. PIOVANI D, Pansieri C, Peyrin-Biroulet L, Danese S, et al
    Confounding and bias in observational studies in inflammatory bowel disease: a meta-epidemiological study.
    Aliment Pharmacol Ther. 2020 Dec 9. doi: 10.1111/apt.16222.
    >> Share

  494. WILS P, Seksik P, Stefanescu C, Nancey S, et al
    Safety of ustekinumab or vedolizumab in pregnant inflammatory bowel disease patients: a multicentre cohort study.
    Aliment Pharmacol Ther. 2020 Dec 7. doi: 10.1111/apt.16192.
    >> Share

  495. LO CH, Khalili H, Lochhead P, Song M, et al
    Immune-mediated diseases and risk of Crohn's disease or ulcerative colitis: a prospective cohort study.
    Aliment Pharmacol Ther. 2020 Dec 5. doi: 10.1111/apt.16210.
    >> Share

  496. WORLEY G, Almoudaris A, Bassett P, Segal J, et al
    Colectomy rates for ulcerative colitis in England 2003-2016.
    Aliment Pharmacol Ther. 2020 Dec 2. doi: 10.1111/apt.16202.
    >> Share

  497. REUKEN PA, Wust M, Loffler B, Bauer M, et al
    Letter: SARS-CoV-2-induced gastrointestinal inflammation.
    Aliment Pharmacol Ther. 2020;52.
    >> Share

    November 2020
  498. DOHOS D, Hanak L, Szakacs Z, Kiss S, et al
    Systematic review with meta-analysis: the effects of immunomodulator or biological withdrawal from mono- or combination therapy in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2020 Nov 28. doi: 10.1111/apt.16182.
    >> Share

  499. BROUSSARD D, Riviere P, Bonnet J, Fotsing G, et al
    Impact of abdominal or pelvic radiotherapy on disease activity in inflammatory bowel disease: a multicentre cohort study from the GETAID.
    Aliment Pharmacol Ther. 2020 Nov 26. doi: 10.1111/apt.16176.
    >> Share

  500. BAGER P, Hvas CL, Rud CL, Dahlerup JF, et al
    Randomised clinical trial: high-dose oral thiamine versus placebo for chronic fatigue in patients with quiescent inflammatory bowel disease.
    Aliment Pharmacol Ther. 2020 Nov 18. doi: 10.1111/apt.16166.
    >> Share

  501. HIBIYA S, Matsuyama Y, Fujii T, Maeyashiki C, et al
    5-aminosalicylate-intolerant patients are at increased risk of colectomy for ulcerative colitis.
    Aliment Pharmacol Ther. 2020 Nov 7. doi: 10.1111/apt.16120.
    >> Share

  502. SCHREINER P, Rossel JB, Biedermann L, Valko PO, et al
    Fatigue in inflammatory bowel disease and its impact on daily activities.
    Aliment Pharmacol Ther. 2020 Nov 7. doi: 10.1111/apt.16145.
    >> Share

  503. GORDON C, Chee D, Hamilton B, Heerasing NM, et al
    Root-cause analyses of missed opportunities for the diagnosis of colorectal cancer in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2020 Nov 7. doi: 10.1111/apt.16155.
    >> Share

  504. MEYER A, Drouin J, Weill A, Carbonnel F, et al
    Pregnancy in women with inflammatory bowel disease: a French nationwide study 2010-2018.
    Aliment Pharmacol Ther. 2020;52:1480-1490.
    >> Share

  505. NICOLAIDES S, Vasudevan A, van Langenberg D
    Letter: rationalising aminosalicylates in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2020;52:1619-1620.
    >> Share

  506. MA C, Singh S, Heatherington J, Panaccione R, et al
    Editorial: is age just a number when it comes to treatment of inflammatory bowel disease?
    Aliment Pharmacol Ther. 2020;52:1615-1616.
    >> Share

  507. ASSCHER VER, Biemans VBC, Hoentjen F, Maljaars PWJ, et al
    Editorial: is age just a number when it comes to treatment of inflammatory bowel disease? Authors' reply.
    Aliment Pharmacol Ther. 2020;52:1617-1618.
    >> Share

  508. CHAPMAN TP, Frias Gomes C, Louis E, Colombel JF, et al
    Letter: rationalising aminosalicylates in inflammatory bowel disease-authors' reply.
    Aliment Pharmacol Ther. 2020;52:1621.
    >> Share

  509. NARULA N, Aruljothy A, Alshahrani AA, Fadida M, et al
    Histologic remission does not offer additional benefit for ulcerative colitis patients in endoscopic remission.
    Aliment Pharmacol Ther. 2020 Nov 1. doi: 10.1111/apt.16147.
    >> Share

  510. VASUDEVAN A, Con D, Nicolaides S, van Langenberg DR, et al
    Editorial: methotrexate vs azathioprine-do differential rates of discontinuation settle the debate? Authors' reply.
    Aliment Pharmacol Ther. 2020;52:1529-1530.
    >> Share

  511. ZULFIQAR M, Deepak P
    Editorial: crystal gazing with magnetic resonance enterography to predict the response to TNF-alpha inhibitors in Crohn's disease.
    Aliment Pharmacol Ther. 2020;52:1531-1532.
    >> Share

  512. FRASER AG
    Methotrexate or azathioprine-do differing rates of discontinuation settle the debate?
    Aliment Pharmacol Ther. 2020;52:1527-1528.
    >> Share

  513. FLANAGAN E, Gibson PR, Wright EK, Moore GT, et al
    Infliximab, adalimumab and vedolizumab concentrations across pregnancy and vedolizumab concentrations in infants following intrauterine exposure.
    Aliment Pharmacol Ther. 2020;52:1551-1562.
    >> Share

  514. TAYLOR H, Serrano-Contreras JI, McDonald JAK, Epstein J, et al
    Multiomic features associated with mucosal healing and inflammation in paediatric Crohn's disease.
    Aliment Pharmacol Ther. 2020;52:1491-1502.
    >> Share

  515. RIMOLA J, Fernandez-Clotet A, Capozzi N, Rojas-Farreras S, et al
    Pre-treatment magnetic resonance enterography findings predict the response to TNF-alpha inhibitors in Crohn's disease.
    Aliment Pharmacol Ther. 2020;52:1563-1573.
    >> Share

    October 2020
  516. BANERJEE R, Ravikanth VV, Pal P, Bale G, et al
    NUDT15 C415T variant compared with TPMT genotyping in predicting azathioprine-induced leucopenia: prospective analysis of 1014 inflammatory bowel disease patients in India.
    Aliment Pharmacol Ther. 2020 Oct 27. doi: 10.1111/apt.16137.
    >> Share

  517. PANACCIONE R, Danese S, Sandborn WJ, O'Brien CD, et al
    Ustekinumab is effective and safe for ulcerative colitis through 2 years of maintenance therapy.
    Aliment Pharmacol Ther. 2020 Oct 21. doi: 10.1111/apt.16119.
    >> Share

  518. AMIOT A, Salameh R
    Letter: long-term outcomes of patients with acute severe ulcerative colitis after intravenous steroid therapy-authors' reply.
    Aliment Pharmacol Ther. 2020;52:1252.
    >> Share

  519. FABIAN A, Bor R, Farkas K, Szepes Z, et al
    Letter: long-term outcomes of patients with acute severe ulcerative colitis after intravenous steroid therapy.
    Aliment Pharmacol Ther. 2020;52:1251.
    >> Share

  520. PRENTICE RE, Tjandra D, Garg M, Lubel JS, et al
    Letter: ACE2, IBD and COVID-19-why IBD patients may be at reduced risk of COVID-19.
    Aliment Pharmacol Ther. 2020;52:1422-1423.
    >> Share

  521. BRITTON E, Richardson P, Mian I, Conley T, et al
    Letter: Covid-19-re-initiating clinical services for chronic gastrointestinal diseases. How and when?
    Aliment Pharmacol Ther. 2020;52:1414-1415.
    >> Share

  522. BIEMANS VBC, Hoentjen F, Pierik MJ
    Letter: effectiveness of ustekinumab or vedolizumab in Crohn's disease following anti-TNF failure-getting closer to the truth. Authors' reply.
    Aliment Pharmacol Ther. 2020;52:1255-1256.
    >> Share

  523. LIU K, Cai F, Huang J
    Letter: effectiveness of ustekinumab or vedolizumab in Crohn's disease following anti-TNF failure-getting closer to the truth?
    Aliment Pharmacol Ther. 2020;52:1253-1254.
    >> Share

  524. LAHARIE D, Riviere P
    Editorial: biologics in the therapy of Crohn's disease-the fog clears.
    Aliment Pharmacol Ther. 2020;52:1214-1215.
    >> Share

  525. MERTZ NORGARD B, Friedman S
    Editorial: thiopurine/anti-TNF use during pregnancy-more encouraging safety data. Authors' reply.
    Aliment Pharmacol Ther. 2020;52:1411.
    >> Share

  526. BETTENWORTH D, Bokemeyer A, Kou L, Lopez R, et al
    Systematic review with meta-analysis: efficacy of balloon-assisted enteroscopy for dilation of small bowel Crohn's disease strictures.
    Aliment Pharmacol Ther. 2020;52:1104-1116.
    >> Share

  527. TOWNSEND T, Razanskaite V, Dodd S, Storey D, et al
    Comparative effectiveness of ustekinumab or vedolizumab after one year in 130 patients with anti-TNF-refractory Crohn's disease.
    Aliment Pharmacol Ther. 2020;52:1341-1352.
    >> Share

    September 2020
  528. BATTAT R, Vande Casteele N, Pai RK, Wang Z, et al
    Evaluating the optimum number of biopsies to assess histological inflammation in ulcerative colitis: a retrospective cohort study.
    Aliment Pharmacol Ther. 2020 Sep 27. doi: 10.1111/apt.16083.
    >> Share

  529. JANGI S, Yoon H, Dulai PS, Valasek M, et al
    Predictors and outcomes of histological remission in ulcerative colitis treated to endoscopic healing.
    Aliment Pharmacol Ther. 2020;52:1008-1016.
    >> Share

  530. CHEE D, Goodhand JR, Ahmad T
    Editorial: is pharmacogenetic testing for adverse effects to IBD treatments ready for roll-out?
    Aliment Pharmacol Ther. 2020;52:1076-1077.
    >> Share

  531. APPLETON L, Day AS
    Editorial: serum oncostatin M at baseline predicts mucosal healing in Crohn's disease patients treated with infliximab.
    Aliment Pharmacol Ther. 2020;52:1080-1081.
    >> Share

  532. ROBLIN X, Le Roy B, Paul S
    Editorial: therapeutic drug monitoring for golimumab - ready for prime time?
    Aliment Pharmacol Ther. 2020;52:1078-1079.
    >> Share

  533. BERTANI L, Fornai M, Antonioli L, Blandizzi C, et al
    Editorial: serum oncostatin M at baseline predicts mucosal healing in Crohn's disease patients treated with infliximab-authors' reply.
    Aliment Pharmacol Ther. 2020;52:1082.
    >> Share

  534. KOPYLOV U
    Letter: optimising response to ustekinumab therapy for patients with Crohn's disease-author's reply.
    Aliment Pharmacol Ther. 2020;52:907.
    >> Share

  535. DESAI D, Abraham P
    Letter: monitoring interval for thiopurine therapy - a comment.
    Aliment Pharmacol Ther. 2020;52:910.
    >> Share

  536. HUDSON J, Herfarth HH, Barnes EL
    Letter: optimising response to ustekinumab therapy for patients with Crohn's disease.
    Aliment Pharmacol Ther. 2020;52:906.
    >> Share

  537. JONES K, Baker K, Speight RA, Thompson NP, et al
    Randomised clinical trial: combined impact and resistance training in adults with stable Crohn's disease.
    Aliment Pharmacol Ther. 2020;52:964-975.
    >> Share

  538. BROMS G, Kieler H, Ekbom A, Gissler M, et al
    Paediatric infections in the first 3 years of life after maternal anti-TNF treatment during pregnancy.
    Aliment Pharmacol Ther. 2020;52:843-854.
    >> Share

  539. IBORRA M, Beltran B, Fernandez-Clotet A, Iglesias-Flores E, et al
    Real-world long-term effectiveness of ustekinumab in Crohn's disease: results from the ENEIDA registry.
    Aliment Pharmacol Ther. 2020;52:1017-1030.
    >> Share

    August 2020
  540. KHAN MU, Mushtaq K, Al-Ejji KMAA, Yakoob RA, et al
    Letter: IBD nurse-a pivotal role in the time of the pandemic.
    Aliment Pharmacol Ther. 2020;52:745.
    >> Share

  541. BERTANI L, Antonioli L, Blandizzi C
    Letter: ustekinumab's effectiveness outcomes compared with vedolizumab in Crohn's disease-what about mucosal healing and biomarkers?
    Aliment Pharmacol Ther. 2020;52:751-752.
    >> Share

  542. AL-ANI AH, Rentsch CA, Azim S, Bidgood E, et al
    Letter: IBD nurse-pivotal role in the time of the pandemic. Authors' reply.
    Aliment Pharmacol Ther. 2020;52:746-747.
    >> Share

  543. BIEMANS VBC, Hoentjen F, Pierik MJ
    Letter: ustekinumab's effectiveness compared with vedolizumab in Crohn's disease-what about mucosal healing and biomarkers? Authors' reply.
    Aliment Pharmacol Ther. 2020;52:753-754.
    >> Share

  544. MARSH A, Radford-Smith G
    Editorial: obesity management and IBD-weight loss reduces IBD risk.
    Aliment Pharmacol Ther. 2020;52:731-732.
    >> Share

  545. KANG B, Kim TJ, Choi J, Baek SY, et al
    Adjustment of azathioprine dose should be based on a lower 6-TGN target level to avoid leucopenia in NUDT15 intermediate metabolisers.
    Aliment Pharmacol Ther. 2020;52:459-470.
    >> Share

  546. WALKER GJ, Lin S, Chanchlani N, Thomas A, et al
    Quality improvement project identifies factors associated with delay in IBD diagnosis.
    Aliment Pharmacol Ther. 2020;52:471-480.
    >> Share

  547. BOHM M, Xu R, Zhang Y, Varma S, et al
    Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease.
    Aliment Pharmacol Ther. 2020;52:669-681.
    >> Share

  548. SEGAL JP, Smith PJ
    Editorial: quality improvement project to identify factors associated with a delay in IBD diagnosis.
    Aliment Pharmacol Ther. 2020;52:733-734.
    >> Share

    July 2020
  549. BIEMANS VBC, van der Woude CJ, Dijkstra G, van der Meulen-de Jong AE, et al
    Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn's disease patients with prior failure to anti-TNF treatment.
    Aliment Pharmacol Ther. 2020;52:123-134.
    >> Share

  550. KABIR M, Fofaria R, Arebi N, Bassett P, et al
    Systematic review with meta-analysis: IBD-associated colonic dysplasia prognosis in the videoendoscopic era (1990 to present).
    Aliment Pharmacol Ther. 2020;52:5-19.
    >> Share

  551. KOPYLOV U, Hanzel J, Liefferinckx C, De Marco D, et al
    Effectiveness of ustekinumab dose escalation in Crohn's disease patients with insufficient response to standard-dose subcutaneous maintenance therapy.
    Aliment Pharmacol Ther. 2020;52:135-142.
    >> Share

  552. KOCHAR B, Cai W, Cagan A, Ananthakrishnan AN, et al
    Frailty is independently associated with mortality in 11 001 patients with inflammatory bowel diseases.
    Aliment Pharmacol Ther. 2020;52:311-318.
    >> Share

  553. THOMANN AK, Mak JWY, Zhang JW, Wuestenberg T, et al
    Review article: bugs, inflammation and mood-a microbiota-based approach to psychiatric symptoms in inflammatory bowel diseases.
    Aliment Pharmacol Ther. 2020;52:247-266.
    >> Share

  554. DUMONT LM, Landman C, Sokol H, Beaugerie L, et al
    Increased risk of permanent stoma in Crohn's disease associated with hidradenitis suppurativa: a case-control study.
    Aliment Pharmacol Ther. 2020;52:303-310.
    >> Share

  555. BERTANI L, Fornai M, Fornili M, Antonioli L, et al
    Serum oncostatin M at baseline predicts mucosal healing in Crohn's disease patients treated with infliximab.
    Aliment Pharmacol Ther. 2020;52:284-291.
    >> Share

    June 2020
  556. YANG E, Panaccione N, Whitmire N, Dulai PS, et al
    Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn's disease.
    Aliment Pharmacol Ther. 2020;51:1031-1038.
    >> Share

  557. LU C, Baraty B, Lee Robertson H, Filyk A, et al
    Systematic review: medical therapy for fibrostenosing Crohn's disease.
    Aliment Pharmacol Ther. 2020;51:1233-1246.
    >> Share

  558. SRINIVASAN A, van Langenberg DR, Little RD, Sparrow MP, et al
    A virtual clinic increases anti-TNF dose intensification success via a treat-to-target approach compared with standard outpatient care in Crohn's disease.
    Aliment Pharmacol Ther. 2020;51:1342-1352.
    >> Share

  559. PAPOUTSOPOULOU S, Satsangi J, Campbell BJ, Probert CS, et al
    Review article: impact of cigarette smoking on intestinal inflammation-direct and indirect mechanisms.
    Aliment Pharmacol Ther. 2020;51:1268-1285.
    >> Share

  560. CZAJA AJ
    Review article: opportunities to improve and expand thiopurine therapy for autoimmune hepatitis.
    Aliment Pharmacol Ther. 2020;51:1286-1304.
    >> Share

    May 2020
  561. UNGARO RC, Aggarwal S, Topaloglu O, Lee WJ, et al
    Systematic review and meta-analysis: efficacy and safety of early biologic treatment in adult and paediatric patients with Crohn's disease.
    Aliment Pharmacol Ther. 2020;51:831-842.
    >> Share

  562. CHEUNG KS, Chen L, Chan EW, Seto WK, et al
    Nonsteroidal anti-inflammatory drugs but not aspirin are associated with a lower risk of post-colonoscopy colorectal cancer.
    Aliment Pharmacol Ther. 2020;51:899-908.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016